1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

ABSTRACT

The present invention relates to compounds of Formula (II) and more preferably to 1H-pyrrolo[2,3-b]pyridine derivatives of formula (III) and related compounds. The variables are defined in the claims. The compounds are BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis of exemplary compounds as well as pharmacological data thereof (pages 61 to 72; examples 1 to 4; tables). An exemplary compound is e.g. 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-yl methyl)amino]benzenesulfonyl]benzamide (example 1).

REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the filing dates of U.S.Provisional Application No. 62/786,398, filed on Dec. 29, 2018;62/852,974, filed on May 25, 2019; and 62/909,971, filed on Oct. 3,2019, the entire contents of each are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Apoptosis, or programmed cell death, is a conserved and regulatedprocess that is the primary mechanism for the removal of aged, damagedand unnecessary cells. The ability to block apoptotic signaling is a keyhallmark of cancer and is thus important for oncogenesis, tumormaintenance and chemoresistance [Hanahan, D. & Weinberg, R. A. Thehallmarks of cancer. Cell 100, 57-70 (2000).]. Dynamic bindinginteractions between prodeath (for example, BCL-2-associated X protein(BAX), BCL-2 antagonist/killer 1 (BAK), BCL-2-associated agonist of celldeath (BAD), BCL-2-like 11 (BIM), NOXA and BCL-2 binding component 3(PUMA)) and prosurvival (BCL-2, BCL-XL, BCL-2-like 2 (BCL-W), myeloidcell leukemia sequence 1 (MCL-1) and BCL-2-related protein A1 (BFL-1))proteins in the BCL-2 family control commitment to programmed celldeath. Altering the balance among these opposing factions provides onemeans by which cancer cells undermine normal apoptosis and gain asurvival advantage [Youle, R. J. & Strasser, A. The BCL-2 proteinfamily: opposing activities that mediate cell death. Nat. Rev. Mol. CellBiol. 9, 47-59 (2008)].

BCL-2, the first identified apoptotic regulator, was originally clonedfrom the breakpoint of a t(14;18) translocation present in human B celllymphomas [Tsujimoto, Y., et al. Science 228, 1440-1443 (1985); Cleary,M. L., et al Cell 47, 19-28 (1986); Boise, L. H. et al. Cell 74, 597-608(1993)]. This protein has since been shown to have a dominant role inthe survival of multiple lymphoid malignancies [Vaux, D. L., et al pre-Bcells. Nature 335, 440-442 (1988)]. Overexpression of Bcl-2 proteinscorrelates with resistance to chemotherapy, clinical outcome, diseaseprogression, overall prognosis or a combination thereof in variouscancers and disorders of the immune system. Involvement of Bcl-2proteins in bladder cancer, brain cancer, breast cancer, bone marrowcancer, cervical cancer, chronic lymphocytic leukemia, colorectalcancer, esophageal cancer, hepatocellular cancer, lymphoblasticleukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cellorigin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovariancancer, non-small cell lung cancer, prostate cancer, small cell lungcancer, spleen cancer, and the like is described in PCT/US2004/36770,published as WO 2005/049593, and PCT/US2004/37911, published asWO/2005/049594. Involvement of Bcl-2 proteins in immune and autoimmunediseases is described in Current Allergy and Asthma Reports 2003, 3,378-384; British Journal of Hematology 2000, 110(3), 584-90; Blood 2000,95(4), 1283-92; and New England Journal of Medicine 2004, 351(14),1409-1418. Involvement of Bcl-2 proteins in arthritis is disclosed in WO2009/064938. Involvement of Bcl-2 proteins in bone marrow transplantrejection is disclosed in US 2008-0182845 A1. All incorporated herein byreference.

In the last decade, several Bcl-2 inhibitors such as ABT-737, ABT-263,and ABT-199 as shown below have been identified and entered humanclinical trials for cancers treatment,

ABT-737 is discovered by nuclear magnetic resonance (NMR)-basedscreening, parallel synthesis and structure based fragment drug design[Tillman Oltersdorf, et al, Nature, Vol 435, 2005, p 677]. ABT-737 asmall-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-XLand Bcl-w, with an affinity two to three orders of magnitude more potentthan previously reported compounds. Mechanistic studies reveal thatABT-737 does not directly initiate the apoptotic process, but enhancesthe effects of death signals, displaying synergistic cytotoxicity withchemotherapeutics and radiation. ABT-737 exhibitssingle-agent-mechanism-based killing of cells from lymphoma andsmall-cell lung carcinoma lines, as well as primary patient-derivedcells, and in animal models, ABT-737 improves survival, causesregression of established tumors, and produces cures in a highpercentage of the mice. Unfortunately, ABT-737 is not orallybioavailable, and its formulation for intravenous delivery is hamperedby its low aqueous solubility.

After extensive MedChem effort, an orally bioavailable Bcl-2 inhibitorABT-263 (Navitoclax) has been developed [Cheol-Min Park, et al J. Med.Chem. 2008, 51, 6902-6915]. ABT-263 is a potent inhibitor of Bcl-xL,Bcl-2 and Bcl-w with Ki of ≤0.5 nM, ≤1 nM and ≤1 nM. ABT-263 has an IC₅₀of 110 nM against SCLC H146 cell line. When ABT-263 is administered at100 mg/kg/day in the H345 xenograft model, significant antitumorefficacy is observed with 80% TGI and 20% of treated tumors indicatingat least a 50% reduction in tumor volume. Oral administration of ABT-263alone causes complete tumor regressions in xenograft models ofsmall-cell lung cancer and acute lymphoblastic leukemia [Tse C, et al.Cancer Res. 2008, 68(9), 3421-3428]. In the clinical trial, however, theinhibition of BCL-XL by ABT-263 (navitoclax) induces a rapid,concentration-dependent decrease in the number of circulating platelets.This mechanism-based thrombocytopenia is the dose-limiting toxicity ofsingle-agent navitoclax treatment in patients and limits the ability todrive drug concentrations into a highly efficacious range.

Thus, a BCL-2 selective (BCL-XL sparing) inhibitor would culminate insubstantially reduced thrombocytopenia while maintaining efficacy inlymphoid malignancies. The resulting increase in the therapeutic windowshould allow for greater BCL-2 suppression and clinical efficacy inBCL-2-dependent tumor types. After extensive MedChem, ABT-199 (GDC-0199)has been successfully developed [Andrew J Souers, et al, NatureMedicine, Volume 19, 22, p202, 2013]. ABT-199 is a Bcl-2-selectiveinhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xLand Bcl-w, and no activity to Mcl-1. ABT-199 potently inhibits RS4;11cells with EC₅₀ of 8 nM. In addition, ABT-199 induces a rapid apoptosisin RS4;11 cells with cytochrome c release, caspase activation, and theaccumulation of sub-G0/G1 DNA. Quantitative immunoblotting reveals thatsensitivity to ABT-199 correlated strongly with the expression of Bcl-2,including NHL, DLBCL, MCL, AML and ALL cell lines. ABT-199 also inducesapoptosis in CLL with an average EC₅₀ of 3.0 nM. A single dose of 100mg/kg of ABT-199 causes a maximal tumor growth inhibition of 95% andtumor growth delay of 152% in RS4;11 xenografts. ABT-199 also inhibitsxenograft growth (DoHH2, Granta-519) as a single agent or in combinationwith Bendamustine and other agents. Human Phase I and II data showedthat ABT-199 is highly efficacious for CLL who have 17p deletion, andwas approved by FDA in 2016.

WO/2017/132474, WO/2019/040550, and WO/2019/040573 disclosed a novelclass of BCL-2 inhibitors. However, there is still a strong need forcontinuing search in this field of art for more potent BCL-2 inhibitor.

SUMMARY OF THE INVENTION

In a first embodiment, this invention provides compounds of the Formula(I) or an N-oxide thereof, or a pharmaceutically acceptable salt,solvate, polymorph, tautomer, stereoisomer, an isotopic form, or aprodrug of said compound of Formula (I) or N-oxide thereof:

wherein

-   -   Z is —P(═O)(R_(c))—, —C(R_(a)R_(b))—, —C(═C(R_(a)R_(b)))—,        —Si(R_(a)R_(b))—, —C(O)—, —N(R⁰)—, —S(═O)(═NR_(c))—,    -   Q₁ is 6-9 membered heteroaryl;    -   Q₃ is cycloalkyl, cycloalkenyl, bridged cycloalkyl,        heterocycloalkyl, heterocycloalkenyl, aryl or heteroaryl;    -   Q₄ is cycloalkyl, cycloalkenyl, heterocycloalkyl,        heterocycloalkenyl, aryl, or heteroaryl;    -   Q₅ is cycloalkyl, cycloalkenyl, heterocycloalkyl,        heterocycloalkenyl, aryl, heteroaryl, or spiro heterocyclic;    -   Q₆ is 6-membered aryl, or 5-6 membered heteroaryl;    -   Q₇ is 6-membered aryl or 5-6 membered heteroaryl, each of which        is optionally fused with a benzene, heteroarene, cycloalkane,        cycloalkene, heterocycloalkane, or heterocycloalkene;    -   each of R₀, and R⁰, independently, is H or alkyl;    -   each of R₁, R₂, R₃, R₄, R₅, R₆. R₇, R₈, R₉, and R₁₀,        independently, is H, D, alkyl, spiroalkyl, alkenyl, alkynyl,        cycloalkyl, cycloalkenyl, heterocycloalkyl,        spiroheterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl,        halo, nitro, oxo, cyano, OR_(a), SR_(a), alkyl-R_(a),        NH(CH₂)_(p)R_(a), C(O)R_(a), S(O)R_(a), SO₂R_(a), C(O)OR_(a),        OC(O)R_(a), NR_(b)R_(c), C(O)N(R_(b))R_(c), N(R_(b))C(O)R_(c),        —P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c), —S(O)(═N(R_(b)))R_(c),        —N═S(O)R_(b)R_(c), ═NR_(b), SO₂N(R_(b))R_(c), or        N(R_(b))SO₂R_(c), in which said cycloalkyl, cycloalkenyl,        heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is        optionally substituted with one or more R_(d);    -   R_(a), R_(b), R_(c) and R_(d), independently, is H, D, alkyl,        spiroalkyl, alkenyl, alkynyl, halo, cyano, amine, nitro,        hydroxy, ═O, —P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c),        —S(O)(═N(R_(b)))R_(c), —N═S(O)R_(b)R_(c), ═NR_(b), C(O)NHOH,        C(O)OH, C(O)NH₂, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl,        aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino,        alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl,        heterocycloalkyl, spiroheterocycloalkyl, heterocycloalkenyl,        aryl, or heteroaryl, in which said alkyl, cycloalkyl,        cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl,        heteroaryl is optionally substituted with one or more R_(e);    -   R_(e) is H, D, alkyl, spiroalkyl, alkenyl, alkynyl, halo, cyano,        amine, nitro, hydroxy, ═O, C(O)NHOH, alkoxy, alkoxyalkyl,        haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl,        alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo,        halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl,        spiroheterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;    -   W is O or N(R_(a));    -   Z₁ is a bond, (CH₂)_(P), N(H), O, S, C(O), S(O₂), OC(O), C(O)O,        OSO₂, S(O₂)O, C(O)S, SC(O), C(O)C(O), C(O)N(H), N(H)C(O),        S(O₂)N(H), N(H)S(O₂), OC(O)O, OC(O)S, OC(O)N(H), N(H)C(O)O,        N(H)C(O)S, N(H)C(O)N(H), (CH₂)_(p)N(H)(CH₂)_(q),        (CH₂)_(p)N(H)C(O)(CH₂)_(q), (CH₂)_(p)C(O)N(H)(CH₂)_(q),        OC(O)N(H)(CH₂)_(p+1)N(H)(CH₂)_(q), a bivalent alkenyl group, or        a bivalent alkynyl group;    -   L is bond, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,        heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, in        which said alkenyl, alkynyl, cycloalkyl, cycloalkenyl,        heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl is        optionally substituted with one or more R_(d);    -   R₀ and R_(a) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl,        is optionally substituted with one or more R_(d);    -   R⁰ and R₁₀ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl, is optionally        substituted with one or more R_(d);    -   two of R_(d) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(d), is optionally substituted with one or more R_(d);    -   two of R₂ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl of R₂, is        optionally substituted with one or more R_(d);    -   R₃ and R₄ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl of R₃ or R₄, is        optionally substituted with one or more R_(d);    -   two of R₅ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl of R₅, is        optionally substituted with one or more R_(d);    -   R₇ and R₈ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl of R₇ or R₈, is        optionally substituted with one or more R_(d);    -   R₈ and —Z₁-L-R₆ group, taken together with the atom to which        they are attached, may optionally form a cycloalkyl,        cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or        heteroaryl, in which said cycloalkyl, cycloalkenyl,        heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl of R₇,        is optionally substituted with one or more R_(d);    -   R_(b) and R_(c) group, taken together with the atom to which        they are attached, may optionally form a cycloalkyl, or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(b) and R_(c), is optionally substituted with one or more        R_(e);    -   two of R_(d) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl, or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(d), is optionally substituted with one or more R_(e);    -   two of R_(e) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(e) is optionally substituted with one or more groups        selected from H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine,        nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl,        hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl,        alkylcarbonylamino, alkylamino, oxo, halo-alkylamino,        cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl,        aryl, or heteroaryl;    -   each of g and j is, independently, 0, 1, 2, or 3;    -   each of n, v and k is, independently, 0, 1, 2, 3, 4, 5, 6, 7, or        8;    -   s is 0 or 1; and    -   each of m, p, and q is, independently, 0, 1, 2, 3, 4, or 5.

In certain embodiments, the invention provides a compound represented byFormula(II):

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (II) or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(III):

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (III) or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(IV):

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (IV) or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(A), wherein Q₄ is heterocycloalkyl; and Q₅ is phenyl or spiroheterocyclic:

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (A) or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(B), wherein f is 0, 1, or 2; and Z₂ is O, S, or S(O₂), or anN-oxide thereof:

or a pharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug of said compound of Formula(B) or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(C-1) or Formula(C-2):

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (C-1) or Formula (C-2), or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(D-1) or Formula(D-2):

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (D-1) or Formula (D-2), or N-oxide thereof.

This invention also provides compounds of the Formula (1) or an N-oxidethereof, or a pharmaceutically acceptable salt, solvate, polymorph,tautomer, stereoisomer, an isotopic form, or a prodrug of said compoundof Formula (1) or N-oxide thereof:

wherein

-   -   Z is —O—, —C(R_(a)R_(b))—, —P(═O)(R_(c))—, —C(═C(R_(a)R_(b)))—,        —Si(R_(a)R_(b))—, —C(O)—, —N(R⁰)—, —S(═O)(═NR_(c))—,    -   Q₄ is cycloalkyl, cycloalkenyl, heterocycloalkyl,        heterocycloalkenyl, aryl, or heteroaryl;    -   Q₅ is cycloalkyl, cycloalkenyl, heterocycloalkyl,        heterocycloalkenyl, aryl, heteroaryl, or spiro heterocyclic;    -   each of R₁, R₂, R₅, and R₉, independently, is H, D, alkyl,        spiroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,        heterocycloalkyl, spiroheterocycloalkyl, heterocycloalkenyl,        aryl, heteroaryl, halo, nitro, oxo, cyano, OR_(a), SR_(a),        alkyl-R_(a), NH(CH₂)_(p)R_(a), C(O)R_(a), S(O)R_(a), SO₂R_(a),        C(O)OR_(a), OC(O)R_(a), NR_(b)R_(c), C(O)N(R_(b))R_(c),        N(R_(b))C(O)R_(c), —P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c),        —S(O)(═N(R_(b)))R_(c), —N═S(O)R_(b)R_(c), ═NR_(b),        SO₂N(R_(b))R_(c), or N(R_(b))SO₂R_(c), in which said cycloalkyl,        cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl,        heteroaryl is optionally substituted with one or more R₄;    -   R_(a), R_(b), R_(c) and R_(d), independently, is H, D, alkyl,        spiroalkyl, alkenyl, alkynyl, halo, cyano, amine, nitro,        hydroxy, ═O, —P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c),        —S(O)(═N(R_(b)))R_(c), —N═S(O)R_(b)R_(c), ═NR_(b), C(O)NHOH,        C(O)OH, C(O)NH₂, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl,        aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino,        alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl,        heterocycloalkyl, spiroheterocycloalkyl, heterocycloalkenyl,        aryl, or heteroaryl, in which said alkyl, cycloalkyl,        cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl,        heteroaryl is optionally substituted with one or more R_(e);    -   R_(e) is H, D, alkyl, spiroalkyl, alkenyl, alkynyl, halo, cyano,        amine, nitro, hydroxy, ═O, C(O)NHOH, alkoxy, alkoxyalkyl,        haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl,        alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo,        halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl,        spiroheterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;    -   Z₃ is a bond, (CH₂)_(P), N(H), O, S, C(O), S(O₂), OC(O), C(O)O,        OSO₂, S(O₂)O, C(O)S, SC(O), C(O)C(O), C(O)N(H), N(H)C(O),        S(O₂)N(H), N(H)S(O₂), OC(O)O, OC(O)S, OC(O)N(H), N(H)C(O)O,        N(H)C(O)S, N(H)C(O)N(H), (CH₂)_(p)N(H)(CH₂)_(q),        (CH₂)_(p)N(H)C(O)(CH₂)_(q), (CH₂)_(p)C(O)N(H)(CH₂)_(q),        OC(O)N(H)(CH₂)_(p+1)N(H)(CH₂)_(q), a bivalent alkenyl group, or        a bivalent alkynyl group;    -   L is bond, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,        heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, in        which said alkenyl, alkynyl, cycloalkyl, cycloalkenyl,        heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl is        optionally substituted with one or more R_(d);    -   two of R_(d) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R₁, is optionally substituted with one or more R_(d);    -   two of R₂ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl of R₂, is        optionally substituted with one or more R_(d);    -   two of R₅ group, taken together with the atom to which they are        attached, may optionally form a cycloalkyl or heterocycloalkyl,        in which said cycloalkyl or heterocycloalkyl of R₅, is        optionally substituted with one or more R_(d);    -   R_(b) and R_(c) group, taken together with the atom to which        they are attached, may optionally form a cycloalkyl, or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(b) and R_(c), is optionally substituted with one or more        R_(e);    -   two of R_(d) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl, or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(d), is optionally substituted with one or more R_(e);    -   two of R_(e) group, taken together with the atom to which they        are attached, may optionally form a cycloalkyl or        heterocycloalkyl, in which said cycloalkyl or heterocycloalkyl        of R_(e) is optionally substituted with one or more groups        selected from H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine,        nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl,        hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl,        alkylcarbonylamino, alkylamino, oxo, halo-alkylamino,        cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl,        aryl, or heteroaryl;    -   each of m, n, v, p, and q is, independently, 0, 1, 2, 3, 4, or        5.

In certain embodiments, the invention provides a compound represented byFormula(2) wherein Q₄ is 5-6 membered heterocycloalkyl:

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (2), or N-oxide thereof.

In certain embodiments, the invention provides a compound represented byFormula(3):

or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug ofsaid compound of Formula (3), or N-oxide thereof.

A modified compound of any one of such compounds including amodification having an improved (e.g., enhanced, greater) pharmaceuticalsolubility, stability, bioavailability, and/or therapeutic index ascompared to the unmodified compound is also contemplated. Exemplarymodifications include (but are not limited to) applicable prodrugderivatives, and deuterium-enriched compounds.

Also within the scope of this invention is a pharmaceutical compositioncontaining one or more of the compounds (such as any one of those inFormulae (A)-(D), or a pharmaceutically acceptable salt, solvate,polymorph, tautomer, stereoisomer, an isotopic form, or a prodrugthereof or an N-oxide thereof), modifications, and/or salts thereofdescribed herein, and a pharmaceutically acceptable diluent or carrier,for use in treating a neoplastic disease, therapeutic uses thereof, anduse of the compounds for the manufacture of a medicament for treatingthe disease/disorder.

This invention also relates to a method of treating a neoplasticdisease, an autoimmune disease, or a neorodegenerative disease,comprising administering to a subject in need thereof an effectiveamount of one or more compounds of the invention (such as any one ofthose in Formulae (A)-(D), or a pharmaceutically acceptable salt,solvate, polymorph, tautomer, stereoisomer, an isotopic form, or aprodrug thereof or an N-oxide thereof), modifications, and/or saltsthereof described herein, or a pharmaceutical composition comprising thecompound(s) of the invention.

In certain embodiments, the neoplastic disease, autoimmune disease, orneorodegenerative disease is characterized by abnormal (e.g., enhancedor increased) Bcl-2 activity. For example, the neoplastic disease can bea hematological malignancy or cancer including solid tumor; theautoimmune disease can be type I diabetes; and the neorodegenerativedisease can be schizophrenia.

In certain embodiments, the neoplastic disease is myeloma, multiplemyeloma, lymphoma, follicular lymphoma (FL), non-Hodgkin's lymphoma,leukemia, acute leukemia, acute lymphoblastic leukemia (ALL) (such asBCL-2-dependent ALL and pediatric ALL), chronic lymphoblastic leukemia(CLL) (such as relapsed/refractory CLL, del(17p) CLL), chronic myeloidleukemia (CML) (such as blast-crisis CML), mantle cell lymphoma (MCL),diffuse large B-cell lymphoma, lung cancer such as small cell lungcancer (SCLC), melanoma, breast cancer, or prostate cancer, includingdrug-resistant cancer thereof.

In certain embodiments, the method further comprises administering oneor more further treatment(s) effective to treat the neoplastic disease,such as surgery, radiation therapy, a chemotherapeutic agent (such asbendamustine, NL-101(7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide),cisplatin, carboplatin, etoposide, topotecan), a target therapy (e.g.,an anti-CD20 antibody such as rituximab, a Bruton's tyrosine kinaseinhibitor such as ibrutinib and acalabrutinib (ACP-196), a PI3Kδinhibitor such as idelalisib); an antibody-drug conjugate or ADC (suchas anti-CD30 ADC brentuximab vedotin), an immunotherapy (such as ananti-PD-1 antibody including pembrolizumab and nivolumab, or ananti-PD-L1 antibody including atezolizumab, durvalumab, and avelumab),or a CAR-T therapy (such as tisagenlecleucel, axicabtagene ciloleucel).

Also provided herein is the use of one or more compounds of theinvention, or a pharmaceutically acceptable salt thereof, or apharmaceutical composition comprising one or more compounds of theinvention, for the preparation of a medicament for the treatment of theabove-referenced diseases or conditions.

In another embodiment, provided herein the compounds of the invention,or a pharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition comprising one or more of the disclosed compounds are foruse in treating the above-referenced diseases or conditions.

The details of one or more embodiments of the invention are set forth inthe description below. Other features, objects, and advantages of theinvention will be apparent from the description and from the claims. Itshould be understood that all embodiments/features of the invention(compounds, pharmaceutical compositions, methods of make/use, etc)described herein, including any specific features described in theexamples and original claims, can combine with one another unless notapplicable or explicitly disclaimed.

DETAILED DESCRIPTION OF THE INVENTION

Exemplary compounds described herein include, but are not limited to,the following:

-   4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoryl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,    N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoryl)benzamide,-   6-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1    (2H)-one,-   2-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-6-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1(2H)-one,-   2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)vinyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   (R)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   (S)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   (R)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(1-hydroxy-1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   (S)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(1-hydroxy-1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(dimethyl(1H-pyrrolo[2,3-b]pyridin-5-yl)silyl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-sulfonimidoyl)benzamide,-   4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)amino)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-carbonyl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)benzamide,-   2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((2-morpholinoethyl)amino)-3-nitrophenyl)sulfonyl)benzamide,-   2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((5-nitro-3-(tetrahydro-2H-pyran-4-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   N-((3-(1,4-dioxan-2-yl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)benzamide,-   2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-(morpholinomethyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   4′-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   4′-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4′-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1    (6H)-yl)-[1,1′-biphenyl]-4-carboxamide,-   4′-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4′-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-[1,1′-biphenyl]-4-carboxamide,-   4′-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)benzamide,-   4′-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   4′-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4′-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)-[1,1′-biphenyl]-4-carboxamide,-   4′-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4′-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)-[1,1′-biphenyl]-4-carboxamide,-   4′-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-[1,1′-biphenyl]-4-carboxamide,    4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   N-(1-(4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)phenyl)vinyl)-4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrobenzenesulfonamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benz    amide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)benzamide,-   4-(2-((S)-2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benz    amide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((R)-2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)benzamide,-   (S)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   (R)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(2-((R)-2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benz    amide,-   4-(7-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-2-azaspiro[3.5]nonan-2-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(6-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-2-azaspiro[3.3]heptan-2-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   4-(9-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-azaspiro[5.5]undecan-3-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(7-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-2-azaspiro[3.5]nonan-2-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(6-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-2-azaspiro[3.3]heptan-2-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(9-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-azaspiro[5.5]undecan-3-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(7-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-2-azaspiro[3.5]nonan-2-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(6-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-2-azaspiro[3.3]heptan-2-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(9-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-3-azaspiro[5.5]undecan-3-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(7-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-2-azaspiro[3.5]nonan-2-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(6-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-2-azaspiro[3.3]heptan-2-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(9-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-3-azaspiro[5.5]undecan-3-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((3-(morpholinomethyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-((4-methylpiperazin-1-yl)methyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   N-((3-(1,4-dioxan-2-yl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)-4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,-   4-(2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((5-nitro-3-(tetrahydro-2H-pyran-4-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((3-(morpholinomethyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((3-((4-methylpiperazin-1-yl)methyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,-   N—(((S)-3-((R)-1,4-dioxan-2-yl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide,-   2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((5-nitro-3-(tetrahydro-2H-pyran-4-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide.

Further eight compounds described herein below can be synthesized basedon WO2019213151, WO2019213153, and WO2019213160, all incorporated hereinby reference.

-   ethyl    P-(4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)-N-(4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)phenyl)phosphonamidite,-   2-(4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)-3-(4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1    (7H)-yl)phenyl)-1,3,2-oxazaphospholidine 2-oxide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)(methyl)phosphoryl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,-   ethyl    P-(4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)-N-(4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzoyl)phosphonamidite,-   ethyl    P-(4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)-N-(4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)phenyl)phosphonamidite,-   2-(4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)-3-(4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)phenyl)-1,3,2-oxazaphospholidine    2-oxide,-   N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)(methyl)phosphoryl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzamide,-   ethyl    P-(4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)-N-(4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)benzoyl)phosphonamidite.

Compounds of the invention may contain one or more asymmetric carbonatoms. Accordingly, the compounds may exist as diastereomers,enantiomers or mixtures thereof. The syntheses of the compounds mayemploy racemates, diastereomers or enantiomers as starting materials oras intermediates. Diastereomeric compounds may be separated bychromatographic or crystallization methods. Similarly, enantiomericmixtures may be separated using the same techniques or others known inthe art. Each of the asymmetric carbon atoms may be in the R or Sconfiguration, and both of these configurations are within the scope ofthe invention.

Compounds having one or more chiral centers can exist in variousstereoisomeric forms. Stereoisomers are compounds that differ only intheir spatial arrangement. Stereoisomers include all diastereomeric,enantiomeric, and epimeric forms as well as racemates and mixturesthereof.

The term “geometric isomer” refers to cyclic compounds having at leasttwo substituents, wherein the two substituents are both on the same sideof the ring (cis) or wherein the substituents are each on opposite sidesof the ring (trans). When a disclosed compound is named or depicted bystructure without indicating stereochemistry, it is understood that thename or the structure encompasses one or more of the possiblestereoisomers, or geometric isomers, or a mixture of the encompassedstereoisomers or geometric isomers.

When a geometric isomer is depicted by name or structure, it is to beunderstood that the named or depicted isomer exists to a greater degreethan another isomer, that is that the geometric isomeric purity of thenamed or depicted geometric isomer is greater than 50%, such as at least60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight. Geometric isomericpurity is determined by dividing the weight of the named or depictedgeometric isomer in the mixture by the total weight of all of thegeomeric isomers in the mixture.

Racemic mixture means 50% of one enantiomer and 50% of is correspondingenantiomer. When a compound with one chiral center is named or depictedwithout indicating the stereochemistry of the chiral center, it isunderstood that the name or structure encompasses both possibleenantiomeric forms (e.g., both enantiomerically-pure,enantiomerically-enriched or racemic) of the compound. When a compoundwith two or more chiral centers is named or depicted without indicatingthe stereochemistry of the chiral centers, it is understood that thename or structure encompasses all possible diasteriomeric forms (e.g.,diastereomerically pure, diastereomerically enriched and equimolarmixtures of one or more diastereomers (e.g., racemic mixtures) of thecompound.

Enantiomeric and diastereomeric mixtures can be resolved into theircomponent enantiomers or stereoisomers by well-known methods, such aschiral-phase gas chromatography, chiral-phase high performance liquidchromatography, crystallizing the compound as a chiral salt complex, orcrystallizing the compound in a chiral solvent. Enantiomers anddiastereomers also can be obtained from diastereomerically- orenantiomerically-pure intermediates, reagents, and catalysts bywell-known asymmetric synthetic methods.

When a compound is designated by a name or structure that indicates asingle enantiomer, unless indicated otherwise, the compound is at least60%, 70%, 80%, 90%, 99% or 99.9% optically pure (also referred to as“enantiomerically pure”). Optical purity is the weight in the mixture ofthe named or depicted enantiomer divided by the total weight in themixture of both enantiomers.

When the stereochemistry of a disclosed compound is named or depicted bystructure, and the named or depicted structure encompasses more than onestereoisomer (e.g., as in a diastereomeric pair), it is to be understoodthat one of the encompassed stereoisomers or any mixture of theencompassed stereoisomers is included. It is to be further understoodthat the stereoisomeric purity of the named or depicted stereoisomers atleast 60%, 70%, 80%, 90%, 99% or 99.9% by weight. The stereoisomericpurity in this case is determined by dividing the total weight in themixture of the stereoisomers encompassed by the name or structure by thetotal weight in the mixture of all of the stereoisomers.

A modified compound of any one of such compounds including amodification having an improved (e.g., enhanced, greater) pharmaceuticalsolubility, stability, bioavailability and/or therapeutic index ascompared to the unmodified compound is also contemplated. The examplesof modifications include but not limited to the prodrug derivatives, andthe deuterium-enriched compounds. For example:

-   -   Prodrug derivatives: prodrugs, upon administration to a subject,        will converted in vivo into active compounds of the present        invention [Nature Reviews of Drug Discovery, 2008, Volume 7,        p255]. It is noted that in many instances, the prodrugs        themselves also fall within the scope of the range of compounds        according to the present invention. The prodrugs of the        compounds of the present invention can be prepared by standard        organic reaction, for example, by reacting with a carbamoylating        agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl        carbonate, or the like) or an acylating agent. Further examples        of methods and strategies of making prodrugs are described in        Bioorganic and Medicinal Chemistry Letters, 1994, Vol. 4, p.        1985.    -   Deuterium-enriched compounds: deuterium (D or ²H) is a stable,        non-radio active isotope of hydrogen and has an atomic weight of        2.0144. Hydrogen naturally occurs as a mixture of the isotopes        ^(X)H (hydrogen or protium), D (²H or deuterium), and T (³H or        tritium). The natural abundance of deuterium is 0.015%. One of        ordinary skill in the art recognizes that in all chemical        compounds with a H atom, the H atom actually represents a        mixture of H and D, with about 0.015% being D. Thus, compounds        with a level of deuterium that has been enriched to be greater        than its natural abundance of 0.015%, should be considered        unnatural and, as a result, novel over their nonenriched        counterparts.

It should be recognized that the compounds of the present invention maybe present and optionally administered in the form of salts, andsolvates. The invention encompasses any pharmaceutically acceptablesalts and solvates of any one of the above-described compounds andmodifications thereof. For example, it is within the scope of thepresent invention to convert the compounds of the present invention intoand use them in the form of their pharmaceutically acceptable saltsderived from various organic and inorganic acids and bases in accordancewith procedures well known in the art.

When the compounds of the present invention possess a free base form,the compounds can be prepared as a pharmaceutically acceptable acidaddition salt by reacting the free base form of the compound with apharmaceutically acceptable inorganic or organic acid, e.g.,hydrohalides such as hydrochloride, hydrobromide, hydroiodide; othermineral acids such as sulfate, nitrate, phosphate, etc.; and alkyl andmonoarylsulfonates such as ethanesulfonate, toluenesulfonate andbenzenesulfonate; and other organic acids and their corresponding saltssuch as acetate, tartrate, maleate, succinate, citrate, benzoate,salicylate and ascorbate. Further acid addition salts of the presentinvention include, but are not limited to: adipate, alginate, arginate,aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate,camphorsulfonate, caprylate, chloride, chlorobenzoate,cyclopentanepropionate, digluconate, dihydrogenphosphate,dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucicacid), galacturonate, glucoheptanoate, gluconate, glutamate,glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate,hippurate, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate,lactate, lactobionate, malonate, mandelate, metaphosphate,methanesulfonate, methylbenzoate, monohydrogenphosphate,2-naphthalenesulfonate, nicotinate, oxalate, oleate, pamoate, pectinate,persulfate, phenylacetate, 3-phenylpropionate, phosphonate andphthalate. It should be recognized that the free base forms willtypically differ from their respective salt forms somewhat in physicalproperties such as solubility in polar solvents, but otherwise the saltsare equivalent to their respective free base forms for the purposes ofthe present invention.

When the compounds of the present invention possess a free acid form, apharmaceutically acceptable base addition salt can be prepared byreacting the free acid form of the compound with a pharmaceuticallyacceptable inorganic or organic base. Examples of such bases are alkalimetal hydroxides including potassium, sodium and lithium hydroxides;alkaline earth metal hydroxides such as barium and calcium hydroxides;alkali metal alkoxides, e.g., potassium ethanolate and sodiumpropanolate; and various organic bases such as ammonium hydroxide,piperidine, diethanolamine and N-methylglutamine. Also included are thealuminum salts of the compounds of the present invention. Further basesalts of the present invention include, but are not limited to: copper,ferric, ferrous, lithium, magnesium, manganic, manganous, potassium,sodium and zinc salts. Organic base salts include, but are not limitedto, salts of primary, secondary and tertiary amines, substituted aminesincluding naturally occurring substituted amines, cyclic amines andbasic ion exchange resins, e.g., arginine, betaine, caffeine,chloroprocaine, choline, N,N′-dibenzylethylenediamine (benzathine),dicyclohexylamine, diethanolamine, 2-diethylaminoethanol,2-dimethylaminoethanol, ethanolamine, ethylenediamine,N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine,hydrabamine, iso-propylamine, lidocaine, lysine, meglumine,N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamineresins, procaine, purines, theobromine, triethanolamine, triethylamine,trimethylamine, tripropylamine and tris-(hydroxymethyl)-methylamine(tromethamine). It should be recognized that the free acid forms willtypically differ from their respective salt forms somewhat in physicalproperties such as solubility in polar solvents, but otherwise the saltsare equivalent to their respective free acid forms for the purposes ofthe present invention.

In one aspect, a pharmaceutically acceptable salt is a hydrochloridesalt, hydrobromide salt, methanesulfonate, toluenesulfonate, acetate,fumarate, sulfate, bisulfate, succinate, citrate, phosphate, maleate,nitrate, tartrate, benzoate, biocarbonate, carbonate, sodium hydroxidesalt, calcium hydroxide salt, potassium hydroxide salt, tromethaminesalt, or mixtures thereof.

Compounds of the present invention that comprise tertiarynitrogen-containing groups may be quaternized with such agents as (C₁₋₄)alkyl halides, e.g., methyl, ethyl, iso-propyl and tert-butyl chlorides,bromides and iodides; di-(C₁₋₄) alkyl sulfates, e.g., dimethyl, diethyland diamyl sulfates; alkyl halides, e.g., decyl, dodecyl, lauryl,myristyl and stearyl chlorides, bromides and iodides; and aryl (C₁₋₄)alkyl halides, e.g., benzyl chloride and phenethyl bromide. Such saltspermit the preparation of both water- and oil-soluble compounds of theinvention.

Amine oxides, also known as amine-A-oxide and A-oxide, of anti-canceragents with tertiary nitrogen atoms have been developed as prodrugs [MolCancer Therapy. 2004 March; 3(3):233-44]. Compounds of the presentinvention that comprise tertiary nitrogen atoms may be oxidized by suchagents as hydrogen peroxide (H₂O₂), Caro's acid or peracids likemeta-Chloroperoxybenzoic acid (mCPBA) to from amine oxide.

The compounds disclosed therein are bcl-2 inhibitors. The pharmaceuticalcomposition of the present invention comprises one or more bcl-2inhibitors, or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier or diluent.

“Pharmaceutically acceptable carrier” and “pharmaceutically acceptablediluent” refer to a substance that aids the formulation and/oradministration of an active agent to and/or absorption by a subject andcan be included in the compositions of the present disclosure withoutcausing a significant adverse toxicological effect on the subject.Non-limiting examples of pharmaceutically acceptable carriers and/ordiluents include water, NaCl, normal saline solutions, lactatedRinger's, normal sucrose, normal glucose, binders, fillers,disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions(such as Ringer's solution), alcohols, oils, gelatins, carbohydratessuch as lactose, amylose or starch, fatty acid esters,hydroxymethylcellulose, polyvinyl pyrrolidine, and colors, and the like.Such preparations can be sterilized and, if desired, mixed withauxiliary agents such as lubricants, preservatives, stabilizers, wettingagents, emulsifiers, salts for influencing osmotic pressure, buffers,coloring, and/or aromatic substances and the like that do notdeleteriously react with or interfere with the activity of the compoundsprovided herein. One of ordinary skill in the art will recognize thatother pharmaceutical excipients are suitable for use with disclosedcompounds.

The pharmaceutical compositions of the present invention optionallyinclude one or more pharmaceutically acceptable carriers and/or diluentstherefor, such as lactose, starch, cellulose and dextrose. Otherexcipients, such as flavoring agents; sweeteners; and preservatives,such as methyl, ethyl, propyl and butyl parabens, can also be included.More complete listings of suitable excipients can be found in theHandbook of Pharmaceutical Excipients (5^(th) Ed., Pharmaceutical Press(2005)). A person skilled in the art would know how to prepareformulations suitable for various types of administration routes.Conventional procedures and ingredients for the selection andpreparation of suitable formulations are described, for example, inRemington's Pharmaceutical Sciences (2003—20th edition) and in TheUnited States Pharmacopeia: The National Formulary (USP 24 NF19)published in 1999. The carriers, diluents and/or excipients are“acceptable” in the sense of being compatible with the other ingredientsof the pharmaceutical composition and not deleterious to the recipientthereof.

The pharmaceutical compositions of the present invention may furthercomprise other conventional pharmaceutically inactive agents. Any inertexcipient that is commonly used as a carrier or diluent may be used incompositions of the present invention, such as sugars, polyalcohols,soluble polymers, salts and lipids. Sugars and polyalcohols which may beemployed include, without limitation, lactose, sucrose, mannitol, andsorbitol. Illustrative of the soluble polymers which may be employed arepolyoxyethylene, poloxamers, polyvinylpyrrolidone, and dextran. Usefulsalts include, without limitation, sodium chloride, magnesium chloride,and calcium chloride. Lipids which may be employed include, withoutlimitation, fatty acids, glycerol fatty acid esters, glycolipids, andphospholipids.

In addition, the pharmaceutical compositions of the present inventionmay further comprise binders (e.g., acacia, cornstarch, gelatin,carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose,hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g.,cornstarch, potato starch, alginic acid, silicon dioxide, croscarmellosesodium, crospovidone, guar gum, sodium starch glycolate, Primogel),buffers (e.g., tris-HCL, acetate, phosphate) of various pH and ionicstrength, additives such as albumin or gelatin to prevent absorption tosurfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acidsalts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate),permeation enhancers, solubilizing agents (e.g., glycerol, polyethyleneglycerol, cyclodextrins), a glidant (e.g., colloidal silicon dioxide),anti-oxidants (e.g., ascorbic acid, sodium metabisulfite, butylatedhydroxyanisole), stabilizers (e.g., hydroxypropyl cellulose,hydroxypropylmethyl cellulose), viscosity increasing agents (e.g.,carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum),sweeteners (e.g., sucrose, aspartame, citric acid), flavoring agents(e.g., peppermint, methyl salicylate, or orange flavoring),preservatives (e.g., Thimerosal, benzyl alcohol, parabens), lubricants(e.g., stearic acid, magnesium stearate, polyethylene glycol, sodiumlauryl sulfate), flow-aids (e.g., colloidal silicon dioxide),plasticizers (e.g., diethyl phthalate, triethyl citrate), emulsifiers(e.g., carbomer, hydroxypropyl cellulose, sodium lauryl sulfate, methylcellulose, hydroxyethyl cellulose, carboxymethylcellulose sodium),polymer coatings (e.g., poloxamers or poloxamines), coating and filmforming agents (e.g., ethyl cellulose, acrylates, polymethacrylates)and/or adjuvants.

In one embodiment, the pharmaceutical compositions are prepared withcarriers that will protect the compound against rapid elimination fromthe body, such as a controlled release formulation, including implantsand microencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid.Methods for preparation of such formulations will be apparent to thoseskilled in the art. The materials can also be obtained commercially fromAlza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions(including liposomes targeted to infected cells with monoclonalantibodies to viral antigens) can also be used as pharmaceuticallyacceptable carriers. These can be prepared according to methods known tothose skilled in the art, for example, as described in U.S. Pat. No.4,522,811.

Additionally, the invention encompasses pharmaceutical compositionscomprising any solid or liquid physical form of the compound of theinvention. For example, the compounds can be in a crystalline form, inamorphous form, and have any particle size. The particles may bemicronized, or may be agglomerated, particulate granules, powders, oils,oily suspensions or any other form of solid or liquid physical form.

When compounds according to the present invention exhibit insufficientsolubility, methods for solubilizing the compounds may be used. Suchmethods are known to those of skill in this art, and include, but arenot limited to, pH adjustment and salt formation, using co-solvents,such as ethanol, propylene glycol, polyethylene glycol (PEG) 300, PEG400, DMA (10-30%), DMSO (10-20%), NMP (10-20%), using surfactants, suchas polysorbate 80, polysorbate 20 (1-10%), cremophor EL, Cremophor RH40,Cremophor RH60 (5-10%), Pluronic F68/Poloxamer 188 (20-50%), SolutolHS15 (20-50%), Vitamin E TPGS, and d-a-tocopheryl PEG 1000 succinate(20-50%), using complexation such as HPpCD and SBEpCD (10-40%), andusing advanced approaches such as micelle, addition of a polymer,nanoparticle suspensions, and liposome formation.

A wide variety of administration methods may be used in conjunction withthe compounds of the present invention. Compounds of the presentinvention may be administered or coadministered orally, parenterally,intraperitoneally, intravenously, intraarterially, transdermally,sublingually, intramuscularly, rectally, transbuccally, intranasally,liposomally, via inhalation, vaginally, intraoccularly, via localdelivery (for example by catheter or stent), subcutaneously,intraadiposally, intraarticularly, or intrathecally. The compoundsaccording to the invention may also be administered or coadministered inslow release dosage forms. Compounds may be in gaseous, liquid,semi-liquid or solid form, formulated in a manner suitable for the routeof administration to be used. For oral administration, suitable solidoral formulations include tablets, capsules, pills, granules, pellets,sachets and effervescent, powders, and the like. Suitable liquid oralformulations include solutions, suspensions, dispersions, emulsions,oils and the like. For parenteral administration, reconstitution of alyophilized powder is typically used.

As used herein, “acyl” means a carbonyl containing substituentrepresented by the formula —C(O)—R in which R is H, alkyl, a carbocycle,a heterocycle, carbocycle-substituted alkyl or heterocycle-substitutedalkyl wherein the alkyl, alkoxy, carbocycle and heterocycle are asdefined herein. Acyl groups include alkanoyl (e.g. acetyl), aroyl (e.g.benzoyl), and heteroaroyl.

“Aliphatic” means a moiety characterized by a straight or branched chainarrangement of constituent carbon atoms and may be saturated orpartially unsaturated with one or more double or triple bonds.

The term “alkyl” refers to a straight or branched hydrocarbon containing1-20 carbon atoms (e.g., C₁-C₁₀, C₁-C₆). Examples of alkyl include, butare not limited to, methyl, methylene, ethyl, ethylene, n-propyl,i-propyl, n-butyl, i-butyl, and t-butyl. Preferably, the alkyl group hasone to ten carbon atoms. More preferably, the alkyl group has one tofour carbon atoms.

The term “alkenyl” refers to a straight or branched hydrocarboncontaining 2-20 carbon atoms (e.g., C₂-C₁₀, C₂-C₆) and one or moredouble bonds. Examples of alkenyl include, but are not limited to,ethenyl, propenyl, and allyl. Preferably, the alkylene group has two toten carbon atoms. More preferably, the alkylene group has two to fourcarbon atoms.

The term “alkynyl” refers to a straight or branched hydrocarboncontaining 2-20 carbon atoms (e.g., C₂-C₁₀, C₂-C₆) and one or moretriple bonds. Examples of alkynyl include, but are not limited to,ethynyl, 1-propynyl, 1- and 2-butynyl, and 1-methyl-2-butynyl.Preferably, the alkynyl group has two to ten carbon atoms. Morepreferably, the alkynyl group has two to four carbon atoms.

The term “alkylamino” refers to an —N(R)-alkyl in which R can be H,alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl,heterocycloalkenyl, aryl, or heteroaryl.

“Alkoxy” means an oxygen moiety having a further alkyl substituent.

“Alkoxycarbonyl” means an alkoxy group attached to a carbonyl group.

“Oxoalkyl” means an alkyl, further substituted with a carbonyl group.The carbonyl group may be an aldehyde, ketone, ester, amide, acid oracid chloride.

The term “cycloalkyl” refers to a saturated hydrocarbon ring systemhaving 3 to 30 carbon atoms (e.g., C₃-C₁₂, C₃-C₈, C₃-C₆). Examples ofcycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The term“cycloalkenyl” refers to a non-aromatic hydrocarbon ring system having 3to 30 carbons (e.g., C₃-C₁₂) and one or more double bonds. Examplesinclude cyclopentenyl, cyclohexenyl, and cycloheptenyl.

The term “heterocycloalkyl” refers to a saturated or unsaturatednonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14membered tricyclic ring system having 1 to 4 heteroatoms (such as O, N,S, B, P, Si, or Se), which may be the same or different. Examples ofheterocycloalkyl groups include, but are not limited to, piperazinyl,pyrrolidinyl, dioxanyl, morpholinyl, and tetrahydrofuranyl.

The term “heterocycloalkenyl” refers to a nonaromatic 5-8 memberedmonocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ringsystem having one or more heteroatoms (such as O, N, S, P, B, Si, or Se)and one or more double bonds.

The term “aryl” refers to a 6-carbon monocyclic, 10-carbon bicyclic,14-carbon tricyclic aromatic ring system. Examples of aryl groupsinclude, but are not limited to, phenyl, naphthyl, and anthracenyl.

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic,8-12 membered bicyclic, or 11-14 membered tricyclic ring system havingone or more heteroatoms (such as O, N, S, P, or Se). Examples ofheteroaryl groups include pyridyl, furyl, imidazolyl, benzimidazolyl,pyrimidinyl, thienyl, quinolinyl, indolyl, and thiazolyl.

Alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl,heterocycloalkenyl, alkylamino, aryl, and heteroaryl mentioned aboveinclude both substituted and unsubstituted moieties. Possiblesubstituents on alkylamino, cycloalkyl, heterocycloalkyl, cycloalkenyl,heterocycloalkenyl, aryl, and heteroaryl include, but are not limitedto, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₂₀ cycloalkyl,C₃-C₂₀ cycloalkenyl, C₁-C₂₀ heterocycloalkyl, C₁-C₂₀ heterocycloalkenyl,C₁-C₁₀ alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C₁-C₁₀alkylamino, arylamino, hydroxy, halo, oxo (O═), thioxo (S═), thio,silyl, C₁-C₁₀ alkylthio, arylthio, C₁-C₁₀ alkylsulfonyl, arylsulfonyl,acylamino, aminoacyl, aminothioacyl, amidino, mercapto, amido,thioureido, thiocyanato, sulfonamido, guanidine, ureido, cyano, nitro,acyl, thioacyl, acyloxy, carbamido, carbamyl, carboxyl, and carboxylicester. On the other hand, possible substituents on alkyl, alkenyl, oralkynyl include all of the above-recited substituents except C₁-C₁₀alkyl. Cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl,aryl, and heteroaryl can also be fused with each other.

“Amino” means a nitrogen moiety having two further substituents whereeach substituent has a hydrogen or carbon atom alpha bonded to thenitrogen. Unless indicated otherwise, the compounds of the inventioncontaining amino moieties may include protected derivatives thereof.Suitable protecting groups for amino moieties include acetyl,tert-butoxycarbonyl, benzyloxycarbonyl, and the like.

“Aromatic” means a moiety wherein the constituent atoms make up anunsaturated ring system, all atoms in the ring system are sp2 hybridizedand the total number of pi electrons is equal to 4n+2. An aromatic ringmay be such that the ring atoms are only carbon atoms or may includecarbon and non-carbon atoms (see Heteroaryl).

“Carbamoyl” means the radical —OC(O)NR_(a)R_(b) where R_(a) and R_(b)are each independently two further substituents where a hydrogen orcarbon atom is alpha to the nitrogen. It is noted that carbamoylmoieties may include protected derivatives thereof.

Examples of suitable protecting groups for carbamoyl moieties includeacetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like. It isnoted that both the unprotected and protected derivatives fall withinthe scope of the invention.

“Carbonyl” means the radical —C(O)—. It is noted that the carbonylradical may be further substituted with a variety of substituents toform different carbonyl groups including acids, acid halides, amides,esters, and ketones.

“Carboxy” means the radical —C(O)O—. It is noted that compounds of theinvention containing carboxy moieties may include protected derivativesthereof, i.e., where the oxygen is substituted with a protecting group.Suitable protecting groups for carboxy moieties include benzyl,tert-butyl, and the like.

“Cyano” means the radical —CN.

“Formyl” means the radical —CH═O.

“Formimino” means the radical —HC═NH.

“Halo” means fluoro, chloro, bromo or iodo.

“Halo-substituted alkyl”, as an isolated group or part of a largergroup, means “alkyl” substituted by one or more “halo” atoms, as suchterms are defined in this Application. Halo-substituted alkyl includeshaloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like.

“Hydroxy” means the radical —OH.

“Imine derivative” means a derivative comprising the moiety —C(═NR)—,wherein R comprises a hydrogen or carbon atom alpha to the nitrogen.

“Isomers” mean any compound having identical molecular formulae butdiffering in the nature or sequence of bonding of their atoms or in thearrangement of their atoms in space. Isomers that differ in thearrangement of their atoms in space are termed “stereoisomers.”Stereoisomers that are not mirror images of one another are termed“diastereomers” and stereoisomers that are nonsuperimposable mirrorimages are termed “enantiomers” or sometimes “optical isomers.” A carbonatom bonded to four nonidentical substituents is termed a “chiralcenter.” A compound with one chiral center has two enantiomeric forms ofopposite chirality. A mixture of the two enantiomeric forms is termed a“racemic mixture.”

“Nitro” means the radical —NO₂.

“Protected derivatives” means derivatives of compounds in which areactive site are blocked with protecting groups. Protected derivativesare useful in the preparation of pharmaceuticals or in themselves may beactive as inhibitors. A comprehensive list of suitable protecting groupscan be found in T. W. Greene, Protecting Groups in Organic Synthesis,3rd edition, Wiley & Sons, 1999.

The term “substituted” means that an atom or group of atoms has replacedhydrogen as the substituent attached to another group. For aryl andheteroaryl groups, the term “substituted” refers to any level ofsubstitution, namely mono-, di-, tri-, tetra-, or penta-substitution,where such substitution is permitted. The substituents are independentlyselected, and substitution may be at any chemically accessible position.The term “unsubstituted” means that a given moiety may consist of onlyhydrogen substituents through available valencies (unsubstituted).

If a functional group is described as being “optionally substituted,”the function group may be either (1) not substituted, or (2)substituted. If a carbon of a functional group is described as beingoptionally substituted with one or more of a list of substituents, oneor more of the hydrogen atoms on the carbon (to the extent there areany) may separately and/or together be replaced with an independentlyselected optional substituent.

“Sulfide” means —S—R wherein R is H, alkyl, carbocycle, heterocycle,carbocycloalkyl or heterocycloalkyl. Particular sulfide groups aremercapto, alkylsulfide, for example methylsulfide (—S-Me); arylsulfide,e.g., phenylsulfide; aralkylsulfide, e.g., benzylsulfide.

“Sulfinyl” means the radical —S(O)—. It is noted that the sulfinylradical may be further substituted with a variety of substituents toform different sulfinyl groups including sulfinic acids, sulfinamides,sulfinyl esters, and sulfoxides.

“Sulfonyl” means the radical —S(O)(O)—. It is noted that the sulfonylradical may be further substituted with a variety of substituents toform different sulfonyl groups including sulfonic acids, sulfonamides,sulfonate esters, and sulfones.

“Thiocarbonyl” means the radical —C(S)—. It is noted that thethiocarbonyl radical may be further substituted with a variety ofsubstituents to form different thiocarbonyl groups including thioacids,thioamides, thioesters, and thioketones.

“Animal” includes humans, non-human mammals (e.g., non-human primates,rodents, mice, rats, hamsters, dogs, cats, rabbits, cattle, horses,sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds,and the like).

“Bioavailability” as used herein is the fraction or percentage of anadministered dose of a drug or pharmaceutical composition that reachesthe systemic circulation intact. In general, when a medication isadministered intravenously, its bioavailability is 100%. However, when amedication is administered via other routes (e.g., orally), itsbioavailability decreases (e.g., due to incomplete absorption andfirst-pass metabolism). Methods to improve the bioavailability includeprodrug approach, salt synthesis, particle size reduction, complexation,change in physical form, solid dispersions, spray drying, and hot-meltextrusion.

“Disease” specifically includes any unhealthy condition of an animal orpart thereof and includes an unhealthy condition that may be caused by,or incident to, medical or veterinary therapy applied to that animal,i.e., the “side effects” of such therapy.

“Pharmaceutically acceptable” means that which is useful in preparing apharmaceutical composition that is generally safe, non-toxic and neitherbiologically nor otherwise undesirable and includes that which isacceptable for veterinary use as well as human pharmaceutical use.

“Pharmaceutically acceptable salts” means organic or inorganic salts ofcompounds of the present invention which are pharmaceuticallyacceptable, as defined above, and which possess the desiredpharmacological activity. Such salts include acid addition salts formedwith inorganic acids, or with organic acids. Pharmaceutically acceptablesalts also include base addition salts which may be formed when acidicprotons present are capable of reacting with inorganic or organic bases.Exemplary salts include, but are not limited, to sulfate, citrate,acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate,phosphate, acid phosphate, isonicotinate, lactate, salicylate, acidcitrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate,succinate, maleate, gentisinate, fumarate, gluconate, glucuronate,saccharate, formate, benzoate, glutamate, methane sulfonate “mesylate,”ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e.,1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts, alkali metal (e.g.,sodium and potassium) salts, alkaline earth metal (e.g., magnesium)salts, and ammonium salts. A pharmaceutically acceptable salt mayinvolve the inclusion of another molecule such as an acetate ion, asuccinate ion or other counter ion. The counter ion may be any organicor inorganic moiety that stabilizes the charge on the parent compound.Furthermore, a pharmaceutically acceptable salt may have more than onecharged atom in its structure. Instances where multiple charged atomsare part of the pharmaceutically acceptable salt can have multiplecounter ions. Hence, a pharmaceutically acceptable salt can have one ormore charged atoms and/or one or more counter ion.

“Pharmacophore,” as defined by The International Union of Pure andApplied Chemistry, is an ensemble of steric and electronic features thatis necessary to ensure the optimal supramolecular interactions with aspecific biological target and to trigger (or block) its biologicalresponse. For example, Camptothecin is the pharmacophore of the wellknown drug topotecan and irinotecan. Mechlorethamine is thepharmacophore of a list of widely used nitrogen mustard drugs likeMelphalan, Cyclophosphamide, Bendamustine, and so on.

“Prodrug” means a compound that is convertible in vivo metabolicallyinto an active pharmaceutical according to the present invention. Forexample, an inhibitor comprising a hydroxyl group may be administered asan ester that is converted by hydrolysis in vivo to the hydroxylcompound.

“Stability” in general refers to the length of time a drug retains itsproperties without loss of potency. Sometimes this is referred to asshelf life. Factors affecting drug stability include, among otherthings, the chemical structure of the drug, impurity in the formulation,pH, moisture content, as well as environmental factors such astemperature, oxidization, light, and relative humidity. Stability can beimproved by providing suitable chemical and/or crystal modifications(e.g., surface modifications that can change hydration kinetics;different crystals that can have different properties), excipients(e.g., anything other than the active substance in the dosage form),packaging conditions, storage conditions, etc.

“Therapeutically effective amount” of a composition described herein ismeant an amount of the composition which confers a therapeutic effect onthe treated subject, at a reasonable benefit/risk ratio applicable toany medical treatment. The therapeutic effect may be objective (i.e.,measurable by some test or marker) or subjective (i.e., subject gives anindication of or feels an effect). An effective amount of thecomposition described above may range from about 0.1 mg/kg to about 500mg/kg, preferably from about 0.2 to about 50 mg/kg. Effective doses willalso vary depending on route of administration, as well as thepossibility of co-usage with other agents. It will be understood,however, that the total daily usage of the compositions of the presentinvention will be decided by the attending physician within the scope ofsound medical judgment. The specific therapeutically effective doselevel for any particular patient will depend upon a variety of factorsincluding the disorder being treated and the severity of the disorder;the activity of the specific compound employed; the specific compositionemployed; the age, body weight, general health, sex and diet of thepatient; the time of administration, route of administration, and rateof excretion of the specific compound employed; the duration of thetreatment; drugs used in combination or contemporaneously with thespecific compound employed; and like factors well known in the medicalarts.

As used herein, the term “treating” refers to administering a compoundto a subject that has a neoplastic or immune disorder, or has a symptomof or a predisposition toward it, with the purpose to cure, heal,alleviate, relieve, alter, remedy, ameliorate, improve, or affect thedisorder, the symptoms of or the predisposition toward the disorder. Theterm “an effective amount” refers to the amount of the active agent thatis required to confer the intended therapeutic effect in the subject.Effective amounts may vary, as recognized by those skilled in the art,depending on route of administration, excipient usage, and thepossibility of co-usage with other agents.

A “subject” refers to a human and a non-human animal. Examples of anon-human animal include all vertebrates, e.g., mammals, such asnon-human primates (particularly higher primates), dog, rodent (e.g.,mouse or rat), guinea pig, cat, and non-mammals, such as birds,amphibians, reptiles, etc. In a preferred embodiment, the subject is ahuman. In another embodiment, the subject is an experimental animal oranimal suitable as a disease model.

“Combination therapy” includes the administration of the subjectcompounds of the present invention in further combination with otherbiologically active ingredients (such as, but not limited to, a secondand different antineoplastic agent) and non-drug therapies (such as, butnot limited to, surgery or radiation treatment). For instance, thecompounds of the invention can be used in combination with otherpharmaceutically active compounds, or non-drug therapies, preferablycompounds that are able to enhance the effect of the compounds of theinvention. The compounds of the invention can be administeredsimultaneously (as a single preparation or separate preparation) orsequentially to the other therapies. In general, a combination therapyenvisions administration of two or more drugs/treatments during a singlecycle or course of therapy.

In one embodiment, the compounds of the invention are administered incombination with one or more of traditional chemotherapeutic agents. Thetraditional chemotherapeutic agents encompass a wide range oftherapeutic treatments in the field of oncology. These agents areadministered at various stages of the disease for the purposes ofshrinking tumors, destroying remaining cancer cells left over aftersurgery, inducing remission, maintaining remission and/or alleviatingsymptoms relating to the cancer or its treatment. Examples of suchagents include, but are not limited to, alkylating agents such asNitrogen Mustards (e.g., Bendamustine, Cyclophosphamide, Melphalan,Chlorambucil, Isofosfamide), Nitrosureas (e.g., Carmustine, Lomustineand Streptozocin), ethylenimines (e.g., thiotepa, hexamethylmelanine),Alkylsulfonates (e.g., Busulfan), Hydrazines and Triazines (e.g.,Altretamine, Procarbazine, Dacarbazine and Temozolomide), and platinumbased agents (e.g., Carboplatin, Cisplatin, and Oxaliplatin); plantalkaloids such as Podophyllotoxins (e.g., Etoposide and Tenisopide),Taxanes (e.g., Paclitaxel and Docetaxel), Vinca alkaloids (e.g.,Vincristine, Vinblastine and Vinorelbine); anti-tumor antibiotics suchas Chromomycins (e.g., Dactinomycin and Plicamycin), Anthracyclines(e.g., Doxorubicin, Daunorubicin, Epirubicin, Mitoxantrone, andIdarubicin), and miscellaneous antibiotics such as Mitomycin andBleomycin; anti-metabolites such as folic acid antagonists (e.g.,Methotrexate), pyrimidine antagonists (e.g., 5-Fluorouracil, Foxuridine,Cytarabine, Capecitabine, and Gemcitabine), purine antagonists (e.g.,6-Mercaptopurine and 6-Thioguanine) and adenosine deaminase inhibitors(e.g., Cladribine, Fludarabine, Nelarabine and Pentostatin);topoisomerase inhibitors such as topoisomerase I inhibitors(Topotecan,Irinotecan), topoisomerase II inhibitors (e.g., Amsacrine, Etoposide,Etoposide phosphate, Teniposide), and miscellaneous anti-neoplasticssuch as ribonucleotide reductase inhibitors (Hydroxyurea),adrenocortical steroid inhibitor (Mitotane), anti-microtubule agents(Estramustine), and retinoids (Bexarotene, Isotretinoin, Tretinoin(ATRA).

In one aspect of the invention, the compounds may be administered incombination with one or more targeted anti-cancer agents that modulateprotein kinases involved in various disease states. Examples of suchkinases may include, but are not limited ABL1, ABL2/ARG, ACK1, AKT1,AKT2, AKT3, ALK, ALK1/ACVRL1, ALK2/ACVR1, ALK4/ACVR1B, ALK5/TGFBR1,ALK6/BMPR1B, AMPK(A1/B1/G1), AMPK(A1/B 1/G2), AMPK(A1/B1/G3),AMPK(A1/B2/G1), AMPK(A2/B1/G1), AMPK(A2/B2/G1), AMPK(A2/B2/G2), ARAF,ARK5/NUAK1, ASK1/MAP3K5, ATM, Aurora A, Aurora B, Aurora C, AXL, BLK,BMPR2, BMX/ETK, BRAF, BRK, BRSK1, BRSK2, BTK, CAMK1a, CAMK1b, CAMK1d,CAMK1g, CAMKIIa, CAMKIIb, CAMKIId, CAMKIIg, CAMK4, CAMKK1, CAMKK2,CDCl₇-DBF4, CDK1-cyclin A, CDK1-cyclin B, CDK1-cyclin E, CDK2-cyclin A,CDK2-cyclin A1, CDK2-cyclin E, CDK3-cyclin E, CDK4-cyclin Dl,CDK4-cyclin D3, CDK5-p25, CDK5-p35, CDK6-cyclin Dl, CDK6-cyclin D3,CDK7-cyclin H, CDK9-cyclin K, CDK9-cyclin T1, CHK1, CHK2, CK1a1, CK1d,CK1epsilon, CK1g1, CK1g2, CK1g3, CK2a, CK2a2, c-KIT, CLK1, CLK2, CLK3,CLK4, c-MER, c-MET, COT1/MAP3K8, CSK, c-SRC, CSF1R, CTK/MATK, DAPK1,DAPK2, DCAMKL1, DCAMKL2, DDR1, DDR2, DLK/MAP3K12, DMPK, DMPK2/CDC42BPG,DNA-PK, DRAK1/STK17A, DYRK1/DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, EEF2K,EGFR, EIF2AK1, EIF2AK2, EIF2AK3, EIF2AK4/GCN2, EPHA1, EPHA2, EPHA3,EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4,ERBB2/HER2, ERBB4/HER4, ERK1/MAPK3, ERK2/MAPK1, ERK5/MAPK7, FAK/PTK2,FER, FES/FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1/VEGFR1, FFT3,FFT4/VEGFR3, FMS, FRK/PTK5, FYN, GCK/MAP4K2, GRK1, GRK2, GRK3, GRK4,GRK5, GRK6, GRK7, GSK3a, GSK3b, Haspin, HCK, HGK/MAP4K4, HIPK1, HIPK2,HIPK3, HIPK4, HPK1/MAP4K1, IGF1R, IKKa/CHUK, IKKb/IKBKB, IKKe/IKBKE, IR,IRAK1, IRAK4, IRR/INSRR, ITK, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3,KDR/VEGFR2, KHS/MAP4K5, FATS1, FATS2, FCK, FCK2/ICK, FKB1, FIMK1,FOK/STKIO, FRRK2, FYN, FYNB, MAPKAPK2, MAPKAPK3, MAPKAPK5/PRAK, MARK1,MARK2/PAR-1B a, MARK3, MARK4, MEK1, MEK2, MEKK1, MEKK2, MEKK3, MEEK,MINK/MINK1, MKK4, MKK6, MFCK/MYFK, MFCK2/MYFK2, MFK1/MAP3K9,MFK2/MAP3K10, MFK3/MAP3K11, MNK1, MNK2, MRCKa/, CDC42BPA, MRCKb/,CDC42BPB, MSK1/RPS6KA5, MSK2/RPS6KA4, MSSK1/STK23, MST1/STK4, MST2/STK3,MST3/STK24, MST4, mTOR/FRAPl, MUSK, MYFK3, MY03b, NEK1, NEK2, NEK3,NEK4, NEK6, NEK7, NEK9, NEK11, NIK/MAP3K14, NEK, OSR1/OXSR1,P38a/MAPK14, P38b/MAPK11, P38d/MAPK13, P38g/MAPK12, P70S6K/RPS6KB1,p70S6Kb/, RPS6KB2, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6, PASK, PBK/TOPK,PDGFRa, PDGFRb, PDK1/PDPK1, PDK1/PDHK1, PDK2/PDHK2, PDK3/PDHK3,PDK4/PDHK4, PHKg1, PHKg2, PI3Ka, (p110a/p85a), PI3Kb, (p110b/p85a),PI3Kd, (p110d/p85a), PI3Kg(p120g), PIM1, PIM2, PIM3, PKA, PKAcb, PKAcg,PKCa, PKCb1, PKCb2, PKCd, PKCepsilon, PKCeta, PKCg, PKCiota, PKCmu/PRKD1, PKCnu/PRKD3, PKCtheta, PKCzeta, PKD2/PRKD2, PKGla, PKGlb, PKG2/PRKG2,PKN1/PRK1, PKN2/PRK2, PKN3/PRK3, PLK1, PLK2, PLK3, PLK4/SAK, PRKX, PYK2,RAF1, RET, RIPK2, RIPK3, RIPK5, ROCK1, ROCK2, RON/MST1R, ROS/ROS1, RSK1,RSK2, RSK3, RSK4, SGK1, SGK2, SGK3/SGKL, SIK1, SIK2, SLK/STK2,SNARK/NUAK2, SRMS, SSTK/TSSK6, STK16, STK22D/TSSK1, STK25/YSK1,STK32b/YANK2, STK32c/YANK3, STK33, STK38/NDR1, STK38L/NDR2, STK39/STLK3,SRPK1, SRPK2, SYK, TAK1, TAOK1, TAOK2/TA01, TAOK3/JIK, TBK1, TEC, TESK1,TGFBR2, TIE2/TEK, TLK1, TLK2, TNIK, TNK1, TRKA, TRKB, TRKC, TRPM7/CHAK1,TSSK2, TSSK3/STK22C, TTBK1, TTBK2, TTK, TXK, TYK1/LTK, TYK2, TYR03/SKY,ULK1, ULK2, ULK3, VRK1, VRK2, WEE1, WNK1, WNK2, WNK3, YES/YES1,ZAK/MLTK, ZAP70, ZIPK/DAPK3, KINASE, MUTANTS, ABL1(E255K), ABL1(F317I),ABL1(G250E), ABL1(H396P), ABL1(M351T), ABL1(Q252H), ABL1(T315I),ABL1(Y253F), ALK (C1156Y), ALK(L1196M), ALK (F1174L), ALK (R1275Q),BRAF(V599E), BTK(E41K), CHK2(I157T), c-Kit(A829P), c-KIT(D816H),c-KIT(D816V), c-Kit(D820E), c-Kit(N822K), C-Kit (T670I), c-Kit(V559D),c-Kit(V559D/V654A), c-Kit(V559D/T670I), C-Kit (V560G), c-KIT(V654A),C-MET(D1228H), C-MET(D1228N), C-MET(F1200I), c-MET(M1250T),C-MET(Y1230A), C-MET(Y 1230C), C-MET(Y1230D), C-MET(Y1230H),c-Src(T341M), EGFR(G719C), EGFR(G719S), EGFR(L858R), EGFR(L861Q),EGFR(T790M), EGFR, (L858R,T790M), EGFR(d746-750/T790M), EGFR(d746-750),EGFR(d747-749/A750P), EGFR(d747-752/P753S), EGFR(d752-759),FGFR1(V561M), FGFR2(N549H), FGFR3(G697C), FGFR3(K650E), FGFR3(K650M),FGFR4(N535K), FGFR4(V550E), FGFR4(V550L), FLT3(D835Y), FLT3(ITD), JAK2(V617F), LRRK2 (G2019S), LRRK2 (I2020T), LRRK2 (R1441C), p38a(T106M),PDGFRa(D842V), PDGFRa(T674I), PDGFRa(V561D), RET(E762Q), RET(G691S),RET(M918T), RET(R749T), RET(R813Q), RET(V804L), RET(V804M), RET(Y791F),TIF2(R849W), TIF2(Y897S), and TIF2(Y1108F).

In another aspect of the invention, the subject compounds may beadministered in combination with one or more targeted anti-cancer agentsthat modulate non-kinase biological targets, pathway, or processes. Suchtargets pathways, or processes include but not limited to heat shockproteins (e.g.HSP90), poly-ADP (adenosine diphosphatcj-ribosc polymerase(PARP), hypoxia-inducible factors (HIF), proteasome, Wnt/Hedgehog/Notchsignaling proteins, TNF-alpha, matrix metalloproteinase, farnesyltransferase, apoptosis pathway (e.g Bcl-xL, Bcl-2, Bcl-w), histonedeacetylases (HDAC), histone acetyltransferases (HAT), andmethyltransferase (e.g histone lysine methyltransferases, histonearginine methyltransferase, DNA methyltransferase, etc), and otherimmunotherapies(e.g anti-PD1, anti-PDL1, anti-CTLA4, CAR-T, IDO, A2Aantagonist etc).

In another aspect of the invention, the compounds of the invention areadministered in combination with one or more of other anti-cancer agentsthat include, but are not limited to, gene therapy, RNAi cancer therapy,chemoprotective agents (e.g., amfostine, mesna, and dexrazoxane),antibody conjugate(e.g brentuximab vedotin, ibritumomab tioxetan),cancer immunotherapy such as Interleukin-2, cancer vaccines (e.g.,sipuleucel-T) or monoclonal antibodies (e.g., Bevacizumab, Alemtuzumab,Rituximab, Trastuzumab, etc).

In another aspect of the invention, the subject compounds areadministered in combination with radiation therapy or surgeries.Radiation is commonly delivered internally (implantation of radioactivematerial near cancer site) or externally from a machine that employsphoton (x-ray or gamma-ray) or particle radiation. Where the combinationtherapy further comprises radiation treatment, the radiation treatmentmay be conducted at any suitable time so long as a beneficial effectfrom the co-action of the combination of the therapeutic agents andradiation treatment is achieved. For example, in appropriate cases, thebeneficial effect is still achieved when the radiation treatment istemporally removed from the administration of the therapeutic agents,perhaps by days or even weeks.

In certain embodiments, the compounds of the invention are administeredin combination with one or more of radiation therapy, surgery, oranti-cancer agents that include, but are not limited to, DNA damagingagents, anti-metabolites, topoisomerase inhibitors, anti-microtubuleagents, kinase inhibitors, epigenetic agents, HSP90 inhibitors, PARPinhibitors, and antibodies targeting VEGF, HER2, EGFR, CD50, CD20, CD30,CD33, etc.

In certain embodiments, the compounds of the invention are administeredin combination with one or more of abarelix, abiraterone acetate,aldesleukin, alemtuzumab, altretamine, anastrozole, asparaginase,bendamustine, bevacizumab, bexarotene, bicalutamide, bleomycin,bortezombi, brentuximab vedotin, busulfan, capecitabine, carboplatin,carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine,clomifene, crizotinib, cyclophosphamide, dasatinib, daunorubicinliposomal, decitabine, degarelix, denileukin diftitox, denileukindiftitox, denosumab, docetaxel, doxorubicin, doxorubicin liposomal,epirubicin, eribulin mesylate, erlotinib, estramustine, etoposidephosphate, everolimus, exemestane, fludarabine, fluorouracil,fotemustine, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin,goserelin acetate, histrelin acetate, hydroxyurea, ibritumomab tiuxetan,idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a,ipilimumab, ixabepilone, lapatinib ditosylate, lenalidomide, letrozole,leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine,melphalan, methotrexate, mitomycin C, mitoxantrone, nelarabine,nilotinib, oxaliplatin, paclitaxel, paclitaxel protein-bound particle,pamidronate, panitumumab, pegaspargase, peginterferon alfa-2b,pemetrexed disodium, pentostatin, raloxifene, rituximab, sorafenib,streptozocin, sunitinib maleate, tamoxifen, temsirolimus, teniposide,thalidomide, toremifene, tositumomab, trastuzumab, tretinoin,uramustine, vandetanib, vemurafenib, vinorelbine, zoledronate,pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, astisagenlecleucel, axicabtagene ciloleucel, radiation therapy, orsurgery.

The invention further provides methods for the prevention or treatmentof a neoplastic disease or autoimmune disease. In one embodiment, theinvention relates to a method of treating a neoplastic disease orautoimmune disease, in a subject in need of treatment comprisingadministering to said subject a therapeutically effective amount of acompound of the invention. In one embodiment, the invention furtherprovides for the use of a compound of the invention in the manufactureof a medicament for halting or decreasing a neoplastic disease orautoimmune disease.

In certain embodiments, the neoplastic disease is a lung cancer, headand neck cancer, central nervous system cancer, prostate cancer,testicular cancer, colorectal cancer, pancreatic cancer, liver cancer,stomach cancer, biliary tract cancer, esophageal cancer,gastrointestinal stromal tumor, breast cancer, cervical cancer, ovariancancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma,basal cell carcinoma, squamous cell carcinoma, bladder cancer, renalcancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome, ormyeloproliferative disease.

The autoimmune diseases that can be affected using compounds andcompositions according to the invention include, but are not limited toallergy, Alzheimer's disease, acute disseminated encephalomyelitis,Addison's disease, ankylosing spondylitis, antiphospholipid antibodysyndrome, asthma, atherosclerosis, autoimmune hemolytic anemia,autoimmune hemolytic and thrombocytopenic states, autoimmune hepatitis,autoimmune inner ear disease, bullous pemphigoid, coeliac disease,chagas disease, chronic obstructive pulmonary disease, chronicIdiopathic thrombocytopenic purpura (ITP), churg-strauss syndrome,Crohn's disease, dermatomyositis, diabetes mellitus type 1,endometriosis, Goodpasture's syndrome (and associated glomerulonephritisand pulmonary hemorrhage), graves' disease, guillain-barré syndrome,hashimoto's disease, hidradenitis suppurativa, idiopathicthrombocytopenic purpura, interstitial cystitis, irritable bowelsyndrome, lupus erythematosus, morphea, multiple sclerosis, myastheniagravis, narcolepsy, neuromyotonia, Parkinson's disease, pemphigusvulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis,psoriasis, psoriatic arthritis, rheumatoid arthritis, schizophrenia,septic shock, scleroderma, Sjogren's disease, systemic lupuserythematosus (and associated glomerulonephritis), temporal arteritis,tissue graft rejection and hyperacute rejection of transplanted organs,vasculitis (ANCA-associated and other vasculitides), vitiligo, andwegener's granulomatosis.

It should be understood that the invention is not limited to theparticular embodiments shown and described herein, but that variouschanges and modifications may be made without departing from the spiritand scope of the invention as defined by the claims.

The compounds according to the present invention may be synthesizedaccording to a variety of schemes. Necessary starting materials may beobtained by standard procedures of organic chemistry. The compounds andprocesses of the present invention will be better understood inconnection with the following representative synthetic schemes andexamples, which are intended as an illustration only and not limiting ofthe scope of the invention.

Various changes and modifications to the disclosed embodiments will beapparent to those skilled in the art and such changes and modificationsincluding, without limitation, those relating to the chemicalstructures, substituents, derivatives, and/or methods of the inventionmay be made without departing from the spirit of the invention and thescope of the appended claims.

A typical approach to synthesize of the intermediate

is described in Scheme 1-1 below: R₁, R₂, m, and n, in general Scheme1-1 are the same as those described in the Summary section above.

In Scheme 1-1, the appropriate ketone starting material 1-1-1 can reactwith tribromophosphine to form the aldehyde intermediate 1-1-2, whichcan couple with Boc-protected piperazine to form the intermediate 1-1-3.After that, 1-1-3 will couple with appropriate phenylboronic acid via aSuzuki reaction to form intermediate 1-1-4, followed by a de-boc processto yield key intermediate 1-1-5.

The intermediate of

can be prepared by the method similar to the Scheme 1-1, and thosedescribed in US9,018,381 by using appropriate staring materials andintermediates.

The intermediate of

can be prepared by the method similar to those described in WO2019210828by using appropriate staring materials and intermediates.

The intermediate of

can be prepared by the method similar to those described in WO2019210828by using appropriate staring materials and intermediates.

The intermediate of

can be prepared by the method similar to those described in WO2019210828by using appropriate staring materials and intermediates.

A typical approach to synthesize of the intermediate

in which R₈ is NO₂ is described in Scheme 2-1 below. R₇, R₈, L, and R₉,in general Scheme 2-1 are the same as those described in the Summarysection above.

In Scheme 2-1, the starting material 2-1-1 reacts with appropriatealcohol or amine will yield 2-1-2.

A typical approach to synthesize of the intermediate

in which R₈ is NO₂ is described in Scheme 2-2 below. R₈, Z₄, L, and R₉,in general Scheme 2-2 are the same as those described in the Summarysection above.

In Scheme 2-2, the bromination of the commercially available 2-2-1results in 2-2-2, and then the reaction of 2-2-2 with appropriate amineprovides 2-2-3. Intramolecular cyclization of 2-2-3 using metalcatalyzed coupling condition such as Buchwald reaction or other couplingreaction known in the literature give 2-2-4. Alternatively, 2-2-4 can beobtained via a 3 step sequence of mesylation of the hydroxyl group of2-2-3, SN2 reaction and intramolecular cyclization.

Similarly, the intermediate of

with different Z_(a) and Z_(b) can be prepared by the method similar tothe Scheme 2-2 by using appropriate staring materials, intermediates,and intramolecular cyclization.

Similarly, the intermediate of

with different Q₈ can be prepared by the method similar to the Scheme2-2 by using appropriate staring materials, intermediates, andintramolecular cyclization.

Similarly, the intermediate of

with different R₇ and Q₇ can be prepared by the method similar to theScheme 2-1 and 2-2 by using appropriate staring materials,intermediates, and intramolecular cyclization.

A typical approach to synthesize of the intermediate

is described in Scheme 3-1 below. R₂, and n, in general Scheme 3-1 arethe same as those described in the Summary section above.

In Scheme 3-1, the starting material undergoes nucleophilic aromaticsubstitution with selected p-fluoro-2-bromo-benzoate to give 3-1-2.

An improved approach to synthesize of target compounds in which Z is—P(O)CH₃-shown in the scheme below is described in Scheme A-1:

In Scheme A-1, the commercially available staring material5-bromo-1H-pyrrolo[2,3-b]pyridine can react with SEM-C1 to form theSEM-protected intermediate A-1-1, which can react with ethylmethylphosphinate to afford the intermediate A-1-2. After that, A-1-2can react with appropriate intermediate A-1-3 to form the intermediateA-1-4, which can undergo a de-protection of SEM group to affords targetcompounds.

Similarly, the compounds of

can be prepared by the method similar to above Schemes by usingappropriate staring materials and intermediates.

Similarly, the compounds of

can be prepared by the method similar to above the Schemes by usingappropriate staring materials and intermediates.

An improved approach to synthesize of target compounds of Formula (IV)is described in Scheme A-2:

In Scheme A-2, the commercially available staring material5-bromo-1H-pyrrolo[2,3-b]pyridine can react with SEM-C1 to form theSEM-protected intermediate A-2-2, which can react with tert-butyl2-cyanoacetate to form the intermediate A-2-3. Heating of A-2-3 in DMSOfor a few hour can lead to the intermediate A-2-4 which can react withA-2-5 to the intermediate A-2-6. After that, A-2-6 can undergo areduction and ring closure reaction to form the intermediate A-2-7,which can reaction with substituted 4-fluoro-3-nitrobenzenesulfonylchloride to yield the intermediate A-2-8. Finally, A-2-8 can react withappropriate side chain to afford the A-2-9, which can undergo ade-protection of SEM group in acid condition to affords targetcompounds.

An approach to synthesize of target compounds of

is described in Scheme A-3:

In Scheme A-3, the intermediate A-2-9 from Scheme A-2 can undergo ade-protection of SEM group under basic condition to affords ring-openedtarget compounds.

An approach to synthesize of target compounds of Formula (3) isdescribed in Scheme A-4:

In Scheme A-4, the intermediate A-4-1 can react with the commerciallyavailable intermediate methyl2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoate to form theintermediate A-4-2, which can undergo a hydrolysis reaction to form thecarbocyclic acid intermediate A-4-3. Finally, the coupling of A-4-3 withappropriate side chain to afford the target compounds.

Similarly, the compounds of Formula (2) can be prepared by schemessimilar to the Scheme A-4 by using appropriate staring materials andintermediates.

Similarly, the compounds of Formula (1) can be prepared by schemessimilar to the Scheme A-4 by using appropriate staring materials andintermediates.

An approach to synthesize of target compounds of Formula (D-1) isdescribed in Scheme A-5:

In Scheme A-5, the intermediate A-5-1 can be prepared by standardorganic reactions or by the methods similar to those described inInternational Application Publication Nos. WO2019/040550 andWO2019/040573. A-5-1 can reaction with methyl 2,4-difluorobenzoate toform the intermediate A-5-2, which can react with A-4-1 to afford theintermediate A-5-3. The hydrolysis of A-5-3 in basic condition will leadto A-5-4, which can react with appropriate side chain followed bydeprotection of SEM group to afford the target compounds.

Similarly, the compounds of Formula (D-1) can be prepared by schemessimilar to the Scheme A-5 by using appropriate staring materials andintermediates.

Similarly, the compounds of Formula (C-1) can be prepared by schemessimilar to the Scheme A-5 by using appropriate staring materials andintermediates.

Similarly, the compounds of Formula (C-2) can be prepared by schemessimilar to the Scheme A-5 by using appropriate staring materials andintermediates.

Similarly, the compounds of Formula (B) can be prepared by schemessimilar to the Scheme A-5 by using appropriate staring materials andintermediates.

Similarly, the compounds of Formula (A) can be prepared by schemessimilar to the Scheme A-5 by using appropriate staring materials andintermediates.

An approach to synthesize of target compounds of Formula (III) isdescribed in Scheme A-6:

In Scheme A-6, the intermediate A-6-0 can reaction with A-6-1 to formthe intermediate A-6-2. The hydrolysis of A-6-2 in basic condition willlead to A-6-3, which can react with appropriate side chain followed bydeprotection of SEM group to afford the target compounds.

Similarly, the compounds of Formula (II) can be prepared by schemessimilar to the Scheme A-6 by using appropriate staring materials andintermediates.

Similarly, the compounds of Formula (I) can be prepared by schemessimilar to the Scheme A-6 by using appropriate staring materials andintermediates.

The compounds and processes of the present invention will be betterunderstood in connection with the following examples, which are intendedas an illustration only and not limiting of the scope of the invention.Various changes and modifications to the disclosed embodiments will beapparent to those skilled in the art and such changes and modificationsincluding, without limitation, those relating to the chemicalstructures, substituents, derivatives, formulations and/or methods ofthe invention may be made without departing from the spirit of theinvention and the scope of the appended claims.

Where NMR data are presented, ¹H spectra were obtained on XL400 (400MHz) and are reported as ppm down field from Me₄Si with number ofprotons, multiplicities, and coupling constants in Hertz indicatedparenthetically. Where HPLC data are presented, analyses were performedusing an Agilent 1100 system. Where LC/MS data are presented, analyseswere performed using an Applied Biosystems API-100 mass spectrometer andShimadzu SCL-10A LC column:

Example INT-1: Preparation of1-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazine

Synthesis of 2-bromo-4,4-dimethylcyclohex-1-enecarbaldehyde 2: Asolution of anhydrous chloroform (57 ml) and anhydrousN,N-dimethylformamide (9 mL) were cooled to ˜3° C. (internaltemperature) under nitrogen before phosphorus tribromide (10 mL, 0.1mol) was introduced dropwise at a rate so that the reaction wasmaintained at ˜3° C. After the addition was complete the reaction wasallowed to warm slowly to ˜10° C. and then the temperature was raised to70° C. where it was maintained for 30 min. The reaction was cooled to rtand 3,3-dimethylcyclohexanone 1 (5 g, 0.04 mol) was added slowly over 20min. After the addition was complete the reaction was warmed to 70° C.and it was stirred for 1.5 h. The mixture was then cooled to 0° C. and asolution of 4M sodium acetate (53 ml) was added slowly. The pH of theresulting solution was adjusted to ˜7 using a solution of 5M NaOH andthe mixture was then extracted with heptanes (100 mL×3). The combinedorganic fractions were dried (Na₂SO₄), filtered and concentrated underreduced pressure to give 2-bromo-4,4-dimethylcyclohex-1-enecarbaldehyde2 (4 g, 49%) as a yellow oil.

Synthesis of 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarbaldehyde3: To a degassed solution of2-bromo-4,4-dimethylcyclohex-1-enecarbaldehyde 2 (5 g, 0.023 mol) and4-chlorophenyl boronic acid (3.6 g, 0.023 mol) in 1,4-dioxane (50 mL) atrt was added a solution of 2M Na₂CO₃ (20.4 ml). Nitrogen was bubbledthrough the mixture for 2 min and then PdCl₂(dppf) (0.5 g) was added.The reaction flask was heated to 120° C. where it was maintained for 3h. After this time the suspension was cooled to rt and filtered throughCelite. The collected solids were washed with additional dichloromethaneand the combined filtrate and washings were concentrated under reducedpressure. Purification by column chromatography on silica withPE:EA=20:1 gave2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarbaldehyde 3 (3 g, 53%)as a white solid. MS: 249[M+H]⁺

Synthesis of (2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol 4:A solution of 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarbaldehyde3 (20 g, 80.6 mmol) in MeOH (100 mL) was cooled to 0° C., NaBH₄ (3.1 g,80.6 mmol) was added portionwise to the reaction at a rate so that thereaction was maintained at 0˜5° C. After added, the mixture was stirredfor 1 h at 0° C. Water was added slowly to the mixture and extractedwith EA (200 mL×3), the organic layer was washed with brine and driedNa₂SO₄, filtered and concentrated under reduced pressure to give(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol 4 (15 g, 75%)as a white solid. MS: 233[M+H−H₂O]⁺

Synthesis of1-(2-(bromomethyl)-5,5-dimethylcyclohex-1-enyl)-4-chlorobenzene 5: Asolution of (2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol 4(15 g, 0.060 mol) and in Et₂O (300 ml) was cooled to 0° C. beforephosphorus tribromide (7.5 mL) was added dropwise to the mixture, afteradded, the mixture was stirred for 1 h at 0° C. for 90 minutes. Thereaction mixture was added H₂O before being extracted with EA. Theorganic layer was washed with a saturated NaHCO₃ solution and brine anddried Na₂SO₄, filtered and concentrated under reduced pressure to give1-(2-(bromomethyl)-5,5-dimethylcyclohex-1-enyl)-4-chlorobenzene 5 (18 g,96%) as a colorless oil.

Synthesis of tert-butyl4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate—Toa solution of 1-bromo-2-(bromomethyl)-5,5-dimethylcyclohex-1-ene 5 (21g, 0.067 mol) and tert-butyl piperazine-1-carboxylate (12.4 g, 0.067mol) in dichloromethane (200 ml) at rt was added TEA (12.2 g, 0.12 mol).The reaction was stirred for 2 h. The reaction mixture was concentratedunder reduced pressure to give the crude product. Purification by columnchromatography on silica with PE:EA=20:1 provided tert-butyl4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate6 (21 g, 75%).

Synthesis of1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazinehydrogen chloride: To a solution of tert-butyl4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate6 (30 g, 0.072 mol) in MeOH (20 ml) was added cone. HCl (50 mL). Thereaction was stirred for 24 hours and then concentrated under reducedpressure. A saturated solution of Na₂CO₃ was added to adjust the pH to˜8-9 and the mixture was extracted with dichloromethane (×2). Thecombined extracts were washed with brine, dried (Na₂SO₄), filtered andconcentrated under reduced pressure. The oil product was treated withMeOH/HCl(g) (3M, 500 mL) and stirred for 1 hour, then concentrated underreduced pressure to get the product1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazinehydrogen chloride IM-14-1 (23 g, 83%). MS: 319[M+H]⁺ ¹H NMR (400 MHz,DMSO) δ 11.51 (s, 1H), 9.60 (s, 1H), 9.18 (s, 1H), 7.45 (d, J=8.2 Hz,2H), 7.15 (d, J=8.0 Hz, 2H), 3.43 (s, 8H), 2.84 (s, 2H), 2.39 (s, 2H),2.03 (s, 2H), 1.45 (t, J=6.0 Hz, 2H), 0.96 (s, 6H).

Example INT-2: Preparation of3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide

To a 500 mL three-neck RB flask equipped with a mechanical stirrer werecharged the 4-chloro-3-nitrobenzenesulfonamide (23.7 g, 100 mmol), DIPEA(12.9 g, 100 mmol), (tetrahydro-2H-pyran-4-yl)methanamine(11.5 g, 100mmol) and acetonitrile (200 mL). The reaction mixture was adjusted to aninternal temperature of 80° C. and agitated for no less than 12 hours.The product solution was cooled down to 40° C. and agitated for no lessthan 1 hour until precipitation observed. The product slurry was furthercooled to 20° C. Water (80 mL) was slowly charged over no less than 1hour, and the mixture cooled to 10° C. and agitated for no less than 2hours before collected by filtration. The wet cake was washed with 1:1mix of acetonitrile:water (40 mL). The wet cake was rinsed with water(80 mL) at 40° C. for no less than 1 hour before collected byfiltration. The wet cake was rinsed with water (20 mL), and dried at 75°C. under vacuum to give the3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide(24.5 g, 78%) as an orange solid, ¹H NMR (400 MHz, DMSO) δ 8.60 (t,J=5.9 Hz, 1H), 8.48 (d, J=2.2 Hz, 1H), 7.84 (dd, J=9.2, 2.0 Hz, 1H),7.54-7.18 (m, 3H), 3.86 (dd, J=11.3, 3.2 Hz, 2H), 3.35 (s, 2H), 3.27 (t,J=10.9 Hz, 2H), 1.92 (ddd, J=11.2, 7.4, 3.9 Hz, 1H), 1.62 (d, J=11.4 Hz,2H), 1.27 (qd, J=12.3, 4.4 Hz, 2H).

Example INT-3: Preparation of4-[[(4-fluorooxan-4-yl)methyl]amino]-3-nitrobenzene-1-sulfonamide

Into a 50-mL round-bottom flask, was placed(4-fluorooxan-4-yl)methanamine hydrochloride (500 mg, 2.95 mmol, 1.00equiv), 4-fluoro-3-nitrobenzene-1-sulfonamide (650 mg, 2.95 mmol, 1.00equiv), tetrahydrofuran (15 mL), Cs₂CO₃ (2.8 g, 8.59 mmol, 3.00 equiv).The resulting solution was stirred for 14 h at 50° C. in an oil bath.The reaction mixture was cooled to room temperature. The resultingmixture was filtered and concentrated under vacuum. The residue wasapplied onto a silica gel column with ethyl acetate/petroleum ether(4:1). This resulted in 650 mg (66%) of4-[[(4-fluorooxan-4-yl)methyl]amino]-3-nitrobenzene-1-sulfonamide as ayellow solid. LCMS (ES, m/z): M+l: 334. H-NMR: (300 MHz, DMSO, ppm): δ8.58 (t, J=6.3 Hz, 1H), 8.49 (d, J=2.1 Hz, 1H), 7.90-7.80 (m, 1H), 7.44(d, J=9.3 Hz, 1H), 7.34 (s, 2H), 3.87-3.70 (m, 4H), 3.61-3.50 (m, 2H),1.95-1.70 (m, 4H).

Example INT-4: Preparation of(S)-4-((1,4-dioxan-2-yl)methylamino)-3-nitrobenzenesulfonamide

Synthesis of (R)-1-chloro-3-(2-chloroethoxy)propan-2-ol:(R)-2-(chloromethyl)oxirane (500.0 g, 5.4 mol, 1.00 equiv) was slowlyadded to a stirred solution of 2-chloroethanol (870.0, 10.8 mol, 2.00equiv) and BF₃.Et₂O (38.0 g, 27 mmol, 0.05 equiv) at 45° C. The reactionmixture was heated on an oil bath for 3 h at 45° C. The reaction mixturewas cooled to R,T and Diethyl ether (100 mL) was added to this solution.The organic layer was washed with water (2×300 mL), dried over magnesiumsulfate, and concentrated to yield a light brown liquid(R)-1-chloro-3-(2-chloroethoxy)propan-2-ol (800.0 g, quantitative).H-NMR: (300 MHz, DMSOM₆, ppm) δ: 3.85-3.47 (m, 9H).

Synthesis of (R)-2-((2-chloroethoxy)methyl)oxirane.(R)-1-chloro-3-(2-chloroethoxy)propan-2-ol (800.0 g, crude, 4.7 mol, 1.0eq) was added dropwise to a stirred solution of NaOH (465.0 g, 11.6 mol,2.5 eq) in water (500 mL) on an ice-bath. The ice-bath was immediatelyremoved after addition of (R)-1-chloro-3-(2-chloroethoxy)propan-2-ol.After stirring 2 h at an ambient temperature, diethyl ether (1.5 L) andwater (500 mL) were added. The organic layer was washed with water (1×50mL), dried over sodium sulfate, and concentrated to give a light brownliquid (R)-2-((2-chloroethoxy)methyl)oxirane (400.0 g). H-NMR: (300 MHz,CDCL3, ppm) δ: 3.82-3.52 (m, 5H), 3.40-3.35 (m, 1H), 3.11-3.09 (m, 1H),2.75-2.73.

Synthesis of (S)-(1,4-dioxan-2-yl)methanol.(R)-2-((2-chloroethoxy)methyl)oxirane (400.0 g, 2.94 mol, 1.0 eq) wasadded to a solution of NaOH (294.0 g, 7.35 mol, 2.5 eq) in water (2900mL) at room temperature. The reaction mixture was heated on an oil bathfor 2 h at 90° C. The resulting solution was cooled to R,T and adjustedPH value to 5 by HCl (6 M). The mixture was concentrated and the residuewas distilled (90-95° C., 0.1 kPa) under vacuum pump to give a colorlessoil (S)-(1,4-dioxan-2-yl)methanol (110 g, 31.7%). H-NMR: (300 MHz,CDCL3, ppm) δ: 3.85-3.42 (m, 9H), 2.15 (bs, 1H).

Synthesis of (R)-(1,4-dioxan-2-yl)methyl methanesulfonate. A mixture of(S)-(l, 4-dioxan-2-yl)methanol (50.0 g, 0.42 mol, 1.0 eq), TEA (63.6 g,0.63 mol, 1.5 eq) and DCM (500 mL) at ice-bath, MsCl (48.1 g, 0.42 mol,1.0 eq) was added dropwise. And then, the ice-bath removed and themixture was stirred at R,T for 2 hours. The reaction mixture was washedby water (2×50 mL) and the organic phase was dried over sodium sulfate,and concentrated to give a light brown oil (R)-(1,4-dioxan-2-yl)methylmethanesulfonate (71.0 g, 83%). H-NMR: (300 MHz, CDCL3, ppm) δ:4.23-4.20 (m, 2H), 3.82-3.56 (m, 6H), 3.50-3.40 (m, 1H), 3.02 (m, 3H).

Synthesis of (S)-(1,4-dioxan-2-yl)methanamine: In 1000 mL autoclave, toa solution of (R)-(1,4-dioxan-2-yl)methyl methanesulfonate (70.0 g, 0.36mol, 1.0 eq) in NH₃.MeOH (7 M, 500 mL) was stirred at 80° C. for 12hours, the reaction mixture was cooled to R,T and concentrated to give alight brown oil (S)-(1,4-dioxan-2-yl)methanamine (30.0 g, 73%). NMR:(300 MHz, DMSO-d₆, ppm) δ: 8.27 (bs, 2H), 3.82-3.42 (m, 6H), 3.24-3.20(m, 1H), 2.98-2.62 (m, 2H).

Synthesis of(S)-4-((1,4-dioxan-2-yl)methylamino)-3-nitrobenzenesulfonamide: Amixture of (S)-(l, 4-dioxan-2-yl)methanamine (25.0 g, 0.21 mol, 1.0 eq),4-fluoro-3-nitrobenzenesulfonamide (46.0 g, 0.21 mol, 1.0 eq) and Cs₂CO₃(137.3 g, 0.42 mol, 2.0 eq) in THF (700 mL) was stirred at 50° C. for 6hours, LCMS showed material was consumed completely, the reactionmixture was cooled R,T and poured into water (3500 mL). The mixture wasfiltrated and collected filtrate cake and dried by oven to give a yellowsolid (S)-4-((1,4-dioxan-2-yl)methylamino)-3-nitrobenzenesulfonamide(60.0 g, 89.5%). H-NMR: (300 MHz, DMSOM₆, ppm) δ: 8.52-8.47 (m, 2H),7.86-7.83 (m, 1H), 7.28-7.00 (m, 3H), 3.82-3.29 (m, 9H).

Example INT-5: Preparation of methyl2-bromo-4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)benzoate

Into a 250-mL round-bottom flask, was placed a solution of Example 1-1,i.e,1-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazine(15.09 g, 47.32 mmol, 1.00 equiv) in DMA (150 mL), DIEA (12.9 g, 99.81mmol, 2.00 equiv), methyl 2-bromo-4-fluorobenzoate (11.6 g, 49.78 mmol,1.00 equiv). The resulting solution was stirred for 12 h at 100 degree.The reaction mixture was cooled to room temperature. The reaction wasthen quenched by the addition of 50 mL of water. The resulting solutionwas extracted with 3×100 mL of ethyl acetate and the organic layerscombined. The resulting mixture was washed with 3×100 mL of brine. Themixture was dried over anhydrous sodium sulfate, then filtered andconcentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (0:1-1:5). This resulted in 7g (crude) of methyl2-bromo-4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)benzoateas yellow oil. LC-MS: (ES, m/z): M+1=533, 531.

Example INT-6: Preparation of2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide

Synthesis of methyl2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoate Into a 20000-mL round-bottom flask, wasplaced 1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine dihydrochloride (600 g, 1.53mol, 1 equiv), methyl 2-bromo-4-fluorobenzoate (357 g, 1.53 mol, 1equiv), DBU (319 g, 6.12 mol, 4 equiv) and DMSO (8000 mL). The resultingsolution was stirred for 20 h at 70 degrees C. LCMS showed material wascompletely consumed. The resulting mixture was cooled to R,T and pouredinto water (32 L). The mixture was filtrated, collection of filter cakeand the filter cake was washed by water (3000 mL×3) and dried by oven togive product 740 g (Y: 91%) methyl2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoateas a white solid. H-NMR-PH-PHNW-4-55-400: (300 MHz, DMSOM₆, ppm) δ: 7.73(d, J=9.0 Hz, 1H), 7.42-7.39 (m, 2H), 7.18-7.12 (m, 3H), 6.97-6.94 (m,1H), 4.00-3.84 (m, 2H), 3.76 (s, 2H), 3.57 (s, 3H), 3.51-3.33 (m, 4H),2.79-2.60 (m, 2H), 2.32-2.30 (m, 2H), 2.03-1.97 (m, 2H), 1.47-1.45 (m,2H), 0.96 (s, 6H).

Synthesis of2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoic acid: Into a 20000-mL round-bottom flask,was placed methyl2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoate(730 g, 1.37 mol, 1 equiv), LiOH (131.5 g, 5.48 mol, 4 equiv) andMeOH/THF/water (4500 mL/3000 mL/1000 mL). The resulting solution wasstirred for 16 h at 70 degrees C. LCMS showed material was completelyconsumed. The resulting mixture was cooled to R,T and concentrated. Theresidue was diluted with water (5000 mL) and the mixture was adjust PHto 3-5 with HCl (6 M), followed by filtrated, collection of filter cakeand dried by oven to give product 650 g (Y: 93%)2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoicacid as a white solid. H-NMR-PH-PHNW-4-55-400: (300 MHz, DMSOM₆, ppm) δ:10.60 (bs, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.42-7.39 (m, 2H), 7.14-7.11 (m,3H), 6.95-6.92 (m, 1H), 4.00-3.84 (m, 2H), 3.76 (s, 2H), 3.51-3.33 (m,4H), 2.79-2.60 (m, 2H), 2.32-2.30 (m, 2H), 2.03-1.97 (m, 2H), 1.47-1.45(m, 2H), 0.97 (s, 6H).

Synthesis of2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide:Into a 20000-mL round-bottom flask, was placed2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoicacid (583 g, 1.13 mol, 1 equiv), DCM (10 L),3-nitro-4-[[(oxan-4-yl)methyl]amino]benzene-1-sulfonamide (338 g, 1.07mol, 0.95 equiv), EDCI (326 g, 1.7 mol, 1.5 equiv), DMAP (551 g, 4.52mol, 4 equiv). The resulting solution was stirred for overnight at 25degrees C. LCMS showed material was completely consumed. The resultingmixture is followed by dilute hydrochloric acid (1.0 M) (1000 mL×3),saturated sodium bicarbonate (1000 mL×3) and brine (1000 mL×1), and thenthe organic phase was dried by Na₂SO₄, filtrated. The filtrate wasconcentrated to give product 857 g (Y: 93%) as a light brown yellowsolid2-bromo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamideas a brown yellow solid. LC-MS: (ES, m/z): M+1=814/816/818, R,T=2.01min. H-NMR-PH-PHNW-4-55-400: (300 MHz, DMSO-d₆, ppm) δ: 8.63-8.61 (m,2H), 7.94-7.92 (m, 1H), 7.37-7.35 (m, 3H), 7.27-7.24 (m, 1H), 7.05-7.02(m, 3H), 6.86-6.83 (m, 1H), 3.87-3.82 (m, 2H), 3.37-3.23 (m, 8H), 2.92(s, 2H), 2.50-2.38 (m, 4H), 2.22-2.20 (m, 2H), 2.00-1.97 (m, 2H),1.64-1.60 (m, 2H), 1.48-1.46 (m, 2H), 1.26-1.20 (m, 2H), 0.97 (s, 6H).

Example INT-6: Preparation of methyl 2-((1H-pyrrolo[2, 3-b]pyridin-5-yl)oxy)-4-bromobenzoate

A mixture of methyl 4-bromo-2-fluorobenzoate (116.5 g, 0.5 mol),1H-pyrrolo[2, 3-b]pyridin-5-ol (67 g, 0.5 mol) and K₂CO₃ (138 g, 1.0mol) in DML (500 mL) was heated at 95° C. for about 16 h. The reactionmixture was cooled to ambient temperature, filtered and the filtrate wasdiluted with DCM (1 L). The resulting solution was washed with H₂O (500mL×2) and concentrated. The residue was recrystallized from EA (200 mL)and PE (400 mL), the cake (68 g) was collected as the first batch. Thefiltrate was concentrated and dissolved in EA (500 mL). The solution waswashed with H₂O (200 mL×2), concentrated, and slurried with EA (25 mL)and PE (25 mL) at reflux for 1 h, cooled to ambient temperature,filtered to give the product (38 g) as the second batch. The two batchesof product were combined to afford the product (106 g, 61.3%) as a brownsolid. MS (ESI, m/e) [M+1]⁺ 346.9, 348.9.

Example INT-7: Preparation of 2-(2-cyclopropylphenyl) pyrrolidine

Step 1: tert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate: Amixture solution of 2-(2-bromophenyl) pyrrolidine (1.13 g, 5 mmol),Boc₂O (2.16 g, 10 mmol), TEA (1.01 g, 10 mmol) and DMAP (cat) in DCM (20mL) was stirred at room temperature for 16 hrs. Then the mixturesolution was concentrated, and the residue was purified bychromatography on silica-gel (eluting with 100% PE to PE/EA=5/1) to givethe product (1.6 g, 98.1%) as a colorless oil. MS (ESI, m/e) [M+1]⁺270.0, 272.0 Step 2: tert-butyl 2-(2-cyclopropylphenyl)pyrrolidine-1-carboxylate: Under a nitrogen atmosphere, a mixture oftert-butyl 2-(2-bromophenyl) pyrrolidine-1-carboxylate (1.56 g, 4.7mmol), cyclopropyl boronic acid (1.23 g, 14.3 mmol), Pd(PPh₃)₄ (540 mg,0.47 mmol) and K₂CO₃ (1.99 g, 14.3 mmol) in 1, 4-dioxane/H₂O (9:1, 20mL) was stirred at 90° C. for 16 hours. Then the reaction mixture wasfiltered and concentrated, the crude product (1.4 g) was used directlyin next step without purification. MS (ESI, m/e) [M+1]⁺ 232.1.

Step 3: 2-(2-cyclopropylphenyl) pyrrolidine: A mixture solution oftert-butyl 2-(2-cyclopropylphenyl) pyrrolidine-1-carboxylate (1.4 g) andTFA (5 mL) in DCM (50 mL) was stirred at room temperature for 16 hours.Then the mixture was concentrated to give a product (1.2 g, crude) as ayellow oil. MS (ESI, m/e) [M+1]⁺ 188.1.

Example INT-8: Preparation of 1-(4-bromophenyl)-2-phenylpyrrolidine

To a degassed solution of 2-phenylpyrrolidine (588 mg, 4 mmol),1-bromo-4-iodobenzene (1.132 g, 16 mmol), BINAP (497 mg, 0.8 mmol) andK-OtBu (1.2 g, 12 mmol) in toluene (25 ml) was added Pd₂ (dba)₃ (366 mg,0.4 mmol). Nitrogen was bubbled through the mixture for 5 min, thenheated to 90° C. and stirred overnight. After cooled to roomtemperature, the reaction mixture was washed with water and brine insequence. The organic layer was dried over anhydrous Na₂SO₄, thenfiltered, concentrated and purified by column chromatography with 5%˜20%EA/PE as eluent to give 1-(4-bromophenyl)-2-phenylpyrrolidine (750 mg,62%) as a colorless oil. MS (ESI, m/e) [M+1]⁺ 302.0, 304.1.

Example INT-9: Preparation of (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane

Step 1: tert-butyl (S)-2-(2-bromophenyl) pyrrolidine-1-carboxylate: To asolution of (S)-2-(2-bromophenyl) pyrrolidine (70 g, 311 mmol) in DCM(200 mL) were added Boc₂O (72.6 g, 333 mmol) and DMAP (cat) at 0° C.After addition, the mixture was stirred at room temperature for 1 hour.Then the mixture solution was washed with saturated aq. NaHCO₃ (100mL×3), brine. The organic phase was dried with anhydrous NaSO₄,filtered, and concentrated to obtain pale brown solid (95g, crude),which was not further purified for next step. MS (ESI, m/e) [M+1]⁺326.1/328.2.

Step 2: tert-butyl (S)-2-(2-cyclopropylphenyl)pyrrolidine-1-carboxylate: Under a N₂ atmosphere, a mixture oftert-butyl (S)-2-(2-bromophenyl) pyrrolidine-1-carboxylate (88 g, 270mmol), cyclopropyl boronic acid (68.9 g, 810 mmol), Pd (dppf)₂Cl₂ (19.7g, 27 mmol) and K₂CO₃ (150 g, 1.08 mol) in 1, 4-dioxane (270 mL) and H₂O(30 mL) was stirred at 90° C. for 16 hours. After the reaction mixturewas cooled to room temperature, the mixture was filtered, and thefiltrate was concentrated in vacuum. The residue was purified bychromatography column on silica (eluent: DCM/CH₃OH=20/1) to obtaintert-butyl (S)-2-(2-cyclopropylphenyl) pyrrolidine-1-carboxylate as paleyellow oil 70 g (yield: 90%). MS (ESI, m/e) [M+1]⁺ 288.1.

Step 3: (S)-2-(2-cyclopropylphenyl) pyrrolidine: To a solution oftert-butyl (S)-2-(2-cyclopropylphenyl) pyrrolidine-1-carboxylate (70g,244 mmol) in DCM (200 mL) was added HCl solution (200 mL, 4M indioxane). After addition, the mixture was stirred for overnight at roomtemperature. After removal of solvent, the residue was diluted withwater (200 mL) and EA (100 mL) under stirring, the separated water phasewas adjusted to PH ˜11 and exacted with DCM (100 mL×2). The combinedorganic phase was dried with anhydrous NaSO₄, filtered, and concentratedto obtain (S)-2-(2-cyclopropylphenyl) pyrrolidine (42 g, crude) as brownoil. MS (ESI, m/e) [M+1]⁺ 188.2.

Step 4: tert-butyl (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate: To the mixture of(S)-2-(2-cyclopropylphenyl) pyrrolidine (3.74 g, 20 mmol) and tert-butyl2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (4.78 g, 20 mmol) in DCM (100mL) was added NaBH(AcO)₃ (8.48 g, 40 mmol) at room temperature andstirred for 2 hours. The reaction mixture was quenched with aq. NaHCO₃solution (200 mL), and then extracted with DCM (200 mL×2). The organiclayer was combined, washed with brine and dried over Na₂SO₄. Afterevaporation in vacuum, the crude product (8.21 g) was obtained as acolorless oil without further purification for next step. MS (ESI, m/e)[M+1]⁺ 411.0.

Step 5: (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane: To a solution of tert-butyl(S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate (8.2 g, 20 mmol) inDCM (200 mL) was added TLA (40 mL) at 20° C. and stirred at roomtemperature overnight. The mixture was concentrated in vacuum anddiluted with DCM (200 mL) and aq. NaOH solution (1N, 200 mL) was addedunder stirring. Then the organic layer was collected and dried overNa₂SO₄. After evaporation in vacuum, the crude product (6.2g) wasobtained as a brown oil without further purification for next step. ¹HNMR (400 MHz, CDCl₃) δ ppm: 7.61 (dd, J=8.0 Hz, J=4.0 Hz, 1H), 7.22-7.11(m, 2H), 7.00-6.96 (m, 1H), 3.94 (t, J=8.0 Hz, 1H), 3.23-3.03 (m, 2H),2.71-2.60 (m, 4H), 2.42-2.20 (m, 2H), 2.07-1.55 (m, 10H), 1.41-1.37 (m,3H), 0.95-0.87 (m, 2H), 0.64-0.53 (m, 2H). MS (ESI, m/e) [M+1]⁺ 311.0.

Example INT-10: Preparation of2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonane

Step 1: methyl 2-bromo-2-(2-bromophenyl) acetate: To a solution ofmethyl 2-(2-bromophenyl) acetate (25 g, 109.14 mmol) in CCl₄ (250 mL)was added NBS (21.37 g, 120.65 mmol) and BPO (1.32 g, 5.46 mmol). Themixture was stirred at 85° C. for 5 hours.

TLC showed reactant was consumed completely. The mixture was poured intoH₂O (200 mL) and extracted with DCM (200 mL×3), washed with brine, driedover Na₂SO₄, filtered and concentrated. The residue was purified byprep-MPLC. Methyl 2-bromo-2-(2-bromophenyl) acetate (20 g) was obtainedas a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.79 (dd, J=1.0, 8.0Hz, 1H), 7.58 (dd, J=1.0, 8.0 Hz, 1H), 7.40-7.34 (m, 1H), 7.21 (dt,J=1.5, 7.7 Hz, 1H), 5.98-5.83 (m, 1H), 3.82 (s, 3H).

Step 2: 3-(2-bromophenyl) piperazin-2-one: To a solution of methyl2-bromo-2-(2-bromophenyl) acetate (20 g, 64.94 mmol) in MeOH (200 mL)was added DIEA (12.67 g, 98.04 mmol) and ethane-1, 2-diamine (7.86 g,130.72 mmol). The mixture was stirred at 25° C. for 12 hours. TLC showedreactant was consumed completely. The mixture was diluted with H₂O (200mL) and extracted with EA (200 mL×3), washed with brine, dried overNa₂SO₄, filtered and concentrated to give crude 3-(2-bromophenyl)piperazin-2-one (14 g) as a white solid, which used in next step withoutfurther purification.

Step 3: tert-butyl2-(2-(2-bromophenyl)-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate:To a solution of 3-(2-bromophenyl) piperazin-2-one (7 g, 27.44 mmol) andtert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (7.22 g, 30.18mmol) in DCE (150 mL) was added AcOH (3.3 g, 54.88 mmol) and NaBH(OAc)₃(11.63 g, 54.88 mmol). The mixture was stirred at 25° C. for 12 hours.TLC showed reactant was consumed completely. The reaction mixture wasextracted with aq. Na₂CO₃ (150 mL) and EA (150 mL×3), dried over Na₂SO₄,filtered and concentrated. The residue was purified by prep-MPLC.Tert-butyl2-(2-(2-bromophenyl)-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(8 g) was obtained as a white solid.

Step 4: tert-butyl2-(2-(2-cyclopropylphenyl)-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate:To a solution of tert-butyl2-(2-(2-bromophenyl)-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(8 g, 16.72 mmol) and cyclopropylboronic acid (2.15 g, 25.08 mmol) indioxane (100 mL) and H₂O (10 mL) was added Cs₂CO₃ (16.34 g, 50.16 mmol)and Pd (dppf) Cl₂ (1.22 g, 1.67 mmol) under N₂ atmosphere. The mixturewas stirred at 85° C. for 2 hours. LC/MS showed reactant was consumedcompletely and one main peak with desired MS signal. The reactionmixture was filtered and concentrated. The residue was diluted with H₂O(50 mL)/EA (50 mL) and extracted with EA (50 mL×2), dried over Na₂SO₄,filtered and concentrated. The residue was purified by prep-MPLC.Tert-butyl2-(2-(2-cyclopropylphenyl)-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(5 g, 68.02% yield) was obtained as a yellow solid. MS (ESI, m/e) [M+1]⁺440.2.

Step 5: tert-butyl2-(2-(2-cyclopropylphenyl)-4-methyl-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate:To a solution of tert-butyl2-(2-(2-cyclopropylphenyl)-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(5 g, 11.37 mmol) in THF (50 mL) was added NaH (0.5 g, 12.51 mmol, 60%)at 0° C. The mixture was stirred at 0° C. for 10 minutes. Then Mel (3.23g, 22.75 mmol) was added at 0° C. The mixture was stirred at 25° C. for5 hours. LC/MS showed reactant was consumed completely and one main peakwith desired MS signal. The reaction mixture was diluted with H₂O (50mL) and extracted with EA (50 mL×3), dried over Na₂SO₄, filtered andconcentrated. The residue was purified by prep-MPLC. Tert-butyl2-(2-(2-cyclopropylphenyl)-4-methyl-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(4.7 g, 91.09% yield) was obtained as a white solid. MS (ESI, m/e)[M+1]⁺ 454.2.

Step 6: tert-butyl2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate:A mixture of tert-butyl2-(2-(2-cyclopropylphenyl)-4-methyl-3-oxopiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(4.7 g, 10.36 mmol, 1 eq) in BH₃. THF (50 mL) was stirred at 70° C. for12 hours. LC/MS showed reactant was consumed completely and one mainpeak with desired MS signal. The reaction mixture was quenched by MeOH(50 mL) at 0° C. and stirred at 25° C. for 30 minutes. Then the mixturewas concentrated to afford tert-butyl2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(4.5 g). MS (ESI, m/e) [M+1]⁺ 440.3.

Step 7:2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonane:A mixture of tert-butyl2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate(4.5 g, 10.24 mmol) in DCM (25 mL) and TFA (25 mL) was stirred at 25° C.for 1 hr. LC/MS showed reactant was consumed completely and one mainpeak with desired MS signal. The reaction mixture was concentrated underreduced pressure to remove solvent. The residue was purified byprep-HPLC (TFA condition). The desired collection was concentrated andwas dilute with H₂O (20 mL) and added aq. Na₂CO₃ to adjust pH to ˜ 9.The mixture was extracted with EA (20 mL×3), dried over Na₂SO₄, filteredand concentrated under reduced pressure to remove solvent.2-(2-(2-cyclopropylphenyl)-4-methylpiperazin-1-yl)-7-azaspiro[3.5](1.2g)was obtained as a white solid. NMR (400 MHz, CDCl₃) δ ppm: 7.48 (s, 1H),7.22-7.12 (m, 2H), 7.01 (s, 1H), 6.39 (s, 1H), 3.96 (d, J=7.3 Hz, 1H),3.04-2.96 (m, 1H), 2.95-2.87 (m, 2H), 2.85-2.65 (m, 5H), 2.30 (s, 3H),2.27 (s, 2H), 2.12 (s, 1H), 1.99 (s, 1H), 1.90-1.81 (m, 1H), 1.75-1.66(m, 1H), 1.60-1.43 (m, 4H), 1.38-1.28 (m, 1H), 1.11 (d, J=4.4, 7.2, 11.5Hz, 1H), 0.99-0.91 (m, 2H), 0.70 (s, 1H), 0.63-0.52 (m, 1H). MS (ESI,m/e) [M+1]⁺ 340.3.

Example 1: Preparation of4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamideSynthesis of5-(methylphosphoroso)-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridine

Into a 250-mL 3-necked round-bottom flask purged and maintained with aninert atmosphere of nitrogen, was added5-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridine (10g, 30.55 mmol, 1.00 equiv), tetrahydrofuran (100 mL). This was followedby the addition of butyllithium (12.22 mL, 30.55 mmol, 1.00 equiv)dropwise with stirring at −78° C. The resulting solution was stirred for1 h at −78° C. Ethyl methylphosphinate (1.65 g, 15.27 mmol, 0.50 equiv)was added and allowed to react, for an additional 1 h at −78° C. Thereaction was then quenched by the addition of 100 mL of 0.5M HCl. Theresulting solution was extracted with 3×100 mL of dichloromethane. Theresulting mixture was washed with 100 mL of brine. The mixture was driedover anhydrous sodium sulfate and concentrated. The residue was appliedonto a silica gel column with dichloromethane/methanol (100:0-90:10).This resulted in 1.2 g (12.65%) of5-(methylphosphoroso)-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridineas light yellow oil. LC-MS: (ES, m/z): 311 [M−H]⁻

Synthesis of4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamide

Into a 40-mL vial purged and maintained with an inert atmosphere ofnitrogen, was added2-bromo-4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamide(315.15 mg, 0.387 mmol, 1.2 equiv),5-(methylphosphoroso)-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridine(100.00 mg, 0.322 mmol, 1.00 equiv), dioxane, Cs₂CO₃ (209.93 mg, 0.644mmol, 2 equiv), copper(I) iodide (61.35 mg, 0.322 mmol, 1 equiv),methyl[2-(methylamino)ethyl]amine (10.58 mg, 0.032 mmol, 0.1 equiv). Theresulting solution was stirred for 4 h at 110° C. The reaction mixturewas cooled to RT. The resulting solution was diluted with 20 mL of H₂O.The resulting solution was extracted with 4×20 mL of dichloromethane.The resulting mixture was washed with 30 mL of brine. The mixture wasdried over anhydrous sodium sulfate and concentrated. The residue wasapplied onto a silica gel column with dichloromethane/methanol(100:0-90:10). This resulted in 230 mg (22.78%) of4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamideas yellow solid. LC-MS: (ES, m/z): 1044 [M−H]⁻

Synthesis of4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamide

Into a 40-mL vial, was added4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamide(225.00 mg, 0.215 mmol, 1.00 equiv), THF (5.00 mL). This was followed bythe addition of TBAF (1M in THF) (4.3. mL, 4.30 mmol, 20 equiv). To thiswas added ethane-1,2-diamine (379.71 mg, 4.30 mmol, 20.00 equiv). Theresulting solution was stirred for 4 h at 70° C. The reaction mixturewas cooled to RT. The resulting solution was diluted with 30 mL of H₂O.The resulting solution was extracted with 4×20 mL of dichloromethane.The resulting mixture was washed with 20 mL of brine. The mixture wasdried over anhydrous sodium sulfate and concentrated. The residue wasapplied onto a silica gel column with dichloromethane/methanol (5:95).The crude product (70 mg) was purified by Prep-HPLC with the followingconditions (IntelFlash-1): Column, c18 silica gel; mobile phase,CH₃CN:H₂O=65% 0.5% NH₃.H₂O; Detector, UV 220 nm. 19 mg product wasobtained. This resulted in 19 mg (9.65%) of4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoroso]-N-[3-nitro-4-[(oxan-4-ylmethyl)amino]benzenesulfonyl]benzamideas yellow solid. LC-MS: (ES, m/z): 914 [M−H]⁻, ¹H NMR (300 MHz, DMSO,ppm):) δ 10.24 (s, 1H), 8.73 (m, 1H), 8.38 (s, 1H), 8.31-7.73 (m, 4H),7.26 (s, 2H), 6.98 (m, 2H), 6.83 (s, 1H), 6.70 (m, 1H), 6.42 (s, 1H),4.25-3.92 (m, 2H), 3.74-3.38 (m, 3H), 3.39-3.04 (m, 8H), 2.88 (s, 3H),2.72 (s, 1H), 2.37 (s, 6H) 2.24 (m, 6H), 2.02 (s, 3H), 1.97 (m, 2H),1.74 (m, 1H), 1.46 (s, 4H), 1.41-1.33 (m, 2), 1.03 (m, 2H), 0.99 (m,10H), 0.09 (s, 3H).

Example 2: Preparation of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-[1H-pyrrolo[2,3-b]pyridin-5-yl]-3,4-dihydroisoquinolin-1-oneSynthesis of5-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridine

Into a 500-mL 3-necked round-bottom flask purged and maintained with aninert atmosphere of nitrogen, was placed a solution of5-bromo-1H-pyrrolo[2,3-b]pyridine (20.00 g, 101.505 mmol, 1.00 equiv) inN,N-dimethylformamide (200.00 mL). This was followed by the addition ofsodium hydride (3.65 g, 152.257 mmol, 1.50 equiv), in portions at 0° C.After 0.5 h stirring, to this was added SEM-C1 (25.38 g, 152.231 mmol,1.50 equiv) dropwise with stirring at 0° C. The resulting solution wasallowed to react with stirring for an additional 3 h at roomtemperature. The reaction was then quenched by the addition of 400 mL ofwater. The resulting solution was extracted with 2×300 mL of ethylacetate The resulting mixture was washed with 2×300 ml of brine. Themixture was dried over anhydrous sodium sulfate and concentrated undervacuum. The residue was applied onto a silica gel column with ethylacetate/petroleum ether (1:3). This resulted in 18 g (54.18%) of5-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridine asdark yellow oil. LCMS (ES, m/z): M+1=328

Synthesis of tert-butyl2-cyano-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)acetate

Into a 250-mL round-bottom flask purged and maintained with an inertatmosphere of nitrogen, was placed5-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridine (8.50g, 25.970 mmol, 1.00 equiv), dioxane (100.00 mL, 1180.408 mmol, 45.45equiv), tert-butyl 2-cyanoacetate (7.33 g, 0.052 mmol, 2.0 equiv),t-BuOK (7.29 g, 0.065 mmol, 2.5 equiv), BrettPhos Pd G3 (2.35 g, 0.003mmol, 0.1 equiv). The resulting solution was stirred for 16 h at 110° C.in an oil bath. The reaction was diluted with 100 mL of water. Theresulting solution was extracted with 2×100 mL of ethyl acetate Theresulting mixture was washed with 2×100 ml of brine. The mixture wasdried over anhydrous sodium sulfate and concentrated under vacuum. Theresidue was applied onto a silica gel column with ethylacetate/petroleum ether (1:3). This resulted in 5.3 g (52.66%) oftert-butyl2-cyano-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)acetateas yellow oil. LCMS (ES, m/z): M+1=388

Synthesis of2-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)acetonitrile

Into a 250-mL round-bottom flask, was placed tert-butyl2-cyano-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)acetate(5.30 g, 13.675 mmol, 1.00 equiv), DMSO (60.00 mL, 844.714 mmol, 61.77equiv), H₂O (15.00 mL, 832.626 mmol, 60.88 equiv), NaCl (4.00 g, 68.443mmol, 5.00 equiv). The resulting solution was stirred for 3 h at 120° C.in an oil bath. The reaction mixture was cooled to room temperature anddiluted with 100 mL of H₂O. The resulting solution was extracted with2×100 mL of ethyl acetate. The resulting mixture was washed with 2×100ml of brine. The mixture was dried over anhydrous sodium sulfate andconcentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (1:3). This resulted in 3.0 g(76.32%) of2-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)acetonitrileas light yellow oil. LCMS (ES, m/z): M+1=288

Synthesis of methyl2-bromo-4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)benzoate

Into a 250-mL round-bottom flask, was placed a solution of1-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazine(15.09 g, 47.32 mmol, 1.00 equiv) in DMA (150 mL), DIEA (12.9 g, 99.81mmol, 2.00 equiv), methyl 2-bromo-4-fluorobenzoate (11.6 g, 49.78 mmol,1.00 equiv). The resulting solution was stirred for 12 h at 100° C. Thereaction mixture was cooled to room temperature. The reaction was thenquenched by the addition of 50 mL of water. The resulting solution wasextracted with 3×100 mL of ethyl acetate and the organic layerscombined. The resulting mixture was washed with 3×100 mL of brine. Themixture was dried over anhydrous sodium sulfate, then filtered andconcentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (0:1-1:5). This resulted in 7g (crude) of methyl2-bromo-4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)benzoateas yellow oil. LC-MS (ES, m/z): M+1=533, 531.

Synthesis of methyl4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[cyano(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)methyl]benzoate

Into a 8-mL sealed tube purged and maintained with an inert atmosphereof nitrogen, was placed 2-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)acetonitrile (100.00 mg, 0.348mmol, 1.00 equiv), dioxane (1.5 mL), methyl2-bromo-4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)benzoate(370.11 mg, 0.696 mmol, 2.00 equiv), t-BuOK (78.08 mg, 0.696 mmol, 2.0equiv), X-Phos (66.34 mg, 0.139 mmol, 0.4 equiv), Pd(OAC)₂ (15.62 mg,0.070 mmol, 0.2 equiv). The resulting solution was stirred for 16 h at100° C. in an oil bath. The reaction was diluted with 5 mL of water. Theresulting solution was extracted with 2×5 mL of ethyl acetate.

The resulting mixture was washed with 2×5 ml of brine. The mixture wasdried over anhydrous sodium sulfate and concentrated under vacuum. Theresidue was applied onto a silica gel column with ethylacetate/petroleum ether (1:2). This reaction was repeated 26 times andobtained 1.0 g (14.99%) of methyl4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[cyano(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)methyl]benzoateas light yellow oil. LC-MS (ES, m/z): M+1=738.

Synthesis of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydro-2H-isoquinolin-1-one

Into a 100-mL 3-necked round-bottom flask purged and maintained with aninert atmosphere of nitrogen, was placed methyl4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-[cyano(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)methyl]benzoate(1.00 g, 1.354 mmol, 1.00 equiv), Toluene (6.00 mL), MeOH (18.00 mL),COCl₂.6H₂O (0.64 g, 0.003 mmol, 2.0 equiv). This was followed by theaddition of NaBH₄ (0.51 g, 0.014 mmol, 10 equiv) at 0° C. The resultingsolution was stirred for 4 h at 0 degrees C. in an ice/salt bath. Thereaction was then quenched by the addition of 50 mL water. The resultingsolution was extracted with 2×50 mL of ethyl acetate. The resultingmixture was washed with 2×50 ml of brine. The mixture was dried overanhydrous sodium sulfate and concentrated under vacuum. The residue wasapplied onto a silica gel column with ethyl acetate/petroleum ether(EA). This resulted in 300 mg (31.18%) of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydro-2H-isoquinolin-1-oneas yellow oil. LC-MS (ES, m/z): M+1=710

Synthesis of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-fluoro-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-one

Into a 8-mL sealed tube purged and maintained with an inert atmosphereof nitrogen, was placed6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydro-2H-isoquinolin-1-one(10.00 mg, 0.014 mmol, 1.00 equiv), THF (0.50 mL). This was followed bythe addition of NaH (1.01 mg, 0.042 mmol, 3.0 equiv) at 0° C. To thiswas added 4-fluoro-3-nitrobenzenesulfonyl chloride (6.75 mg, 0.028 mmol,2.00 equiv) at 0° C. The resulting solution was stirred for 2 h at roomtemperature. The reaction was then quenched by the addition of 3 mLwater. The resulting solution was extracted with 2×5 mL of ethylacetate. The resulting mixture was washed with 2×5 ml of brine. Themixture was dried over anhydrous sodium sulfate and concentrated undervacuum. The residue was applied onto a silica gel column with ethylacetate/petroleum ether (1:2). This reaction was repeated 20 times andobtained 110 mg (42.8%) of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-fluoro-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-oneas a light yellow solid. LC-MS (ES, m/z): M+1=913.

Synthesis of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-one

Into a 8-mL sealed tube, was placed6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-fluoro-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-one(110.00mg, 0.120 mmol, 1.00 equiv), ACN (2.0 mL),1-[(2S)-1,4-dioxan-2-yl]methanamine hydrochloride (36.99 mg, 0.241 mmol,2.00 equiv), Cs₂CO₃ (78.46 mg, 0.241 mmol, 2.0 equiv). The resultingsolution was stirred for 2 h at room temperature. The resulting solutionwas diluted with 5 mL of H₂O. The resulting solution was extracted with2×5 mL of ethyl acetate. The resulting solution was extracted with 2×5mL of ethyl acetate. The resulting mixture was washed with 2×5 ml ofbrine. The mixture was dried over anhydrous sodium sulfate andconcentrated under vacuum. The residue was applied onto a silica gelcolumn with ethyl acetate/petroleum ether (4:1). This resulted in 90 mg(73.95%) of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-oneas a yellow solid. LC-MS (ES, m/z): M+1=1010.

Synthesis of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-[1H-pyrrolo[2,3-b]pyridin-5-yl]-3,4-dihydroisoquinolin-1-one

Into a 8-mL sealed tube, was placed6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-one(30.00 mg, 0.030 mmol, 1.00 equiv), DCM (0.30 mL, 4.719 mmol, 158.99equiv), TFA (0.10 mL, 1.346 mmol, 45.36 equiv), the resulting solutionwas stirred for 16 h at room temperature. The resulting mixture wasconcentrated under vacuum. The crude product was placed ACN (0.50 mL,9.512 mmol, 320.48 equiv), ethylenediamine (5.35 mg, 0.089 mmol, 3.00equiv). The resulting solution was stirred for 24 h at room temperature.The resulting mixture was concentrated under vacuum. The crude productwas purified by Prep-HPLC with the following conditions: Column, XBridgeShield RP18 OBD Column, 5 um, 19*150 mm; mobile phase, Water (0.05%NH₃.H₂O) and ACN (80% Phase B up to 90% in 7 min); Detector, UV 254/220nm. This resulted in 8 mg (30.61%) of6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-[1H-pyrrolo[2,3-b]pyridin-5-yl]-3,4-dihydroisoquinolin-1-oneas a yellow solid. LC-MS: (ES, m/z): M+l: 880. H NMR (300 MHz, DMSO-d6,ppm) δ 11.62 (s, 1H), 8.55 (s, 1H), 8.32 (s, 1H), 8.14 (s, 1H), 7.76 (d,J=8.4 Hz, 1H), 7.43 (s, 1H), 7.36-7.20 (m, 4H), 7.05 (d, J=7.81 Hz, 2H),6.94 (d, J=8.49 Hz, 1H), 6.78-6.70 (m, 1H), 6.66 (s, 1H), 6.26 (s, 1H),4.52 (d, J=19.6 Hz, 2H), 4.23 (d, J=12.4 Hz, 1H), 3.79 (d, J=7.05 Hz,3H), 3.69-3.59 (m, 2H), 3.54-3.42 (m, 2H), 3.25-3.22 (m, 4H), 2.74 (s,3H), 2.19 (s, 7H), 1.97 (s, 2H), 1.40 (s, 2H), 0.94 (s, 6H).

Example 3: Preparation of2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)vinyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide

Into a 8-mL sealed tube, was placed6-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-2-(4-[[(2S)-1,4-dioxan-2-ylmethyl]amino]-3-nitrobenzenesulfonyl)-4-(1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1-one(60.00 mg, 0.059 mmol, 1.00 equiv), ethylenediamine (7.14 mg, 0.119mmol, 2.00 equiv), TBAF (1M in THF, 2 mL). The resulting solution wasstirred for 16 h at 50° C. in an oil bath. The resulting solution wasdiluted with 5 mL of H₂O. The resulting solution was extracted with 2×5mL of ethyl acetate The resulting mixture was washed with 2×5 ml ofbrine. The mixture was dried over anhydrous sodium sulfate andconcentrated under vacuum. The crude product was purified by Prep-HPLCwith the following conditions: Column, XBridge Shield RP18 OBD Column, 5um, 19*150 mm; mobile phase, Water (0.05% NH₃.H₂O) and ACN (25% Phase Bup to 45% in 8 min); Detector, UV 254/220 nm. This resulted in 10 mg(19.13%) of(S)—N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)vinyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)benzamideas a yellow solid. LC-MS (ES, m/z): M+l: 880. ¹H NMR (300 MHz, DMSO-d6,ppm) δ: 11.31 (s, 1H), 8.50 (s, 1H), 8.26 (d, J=2.1 Hz, 1H), 7.96 (s,1H), 7.46 (s, 2H), 7.37 (d, J=8.0 Hz, 2H), 7.31-7.29 (m, 1H), 7.08 (d,J=8.1 Hz, 2H), 6.94 (d, J=8.6 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 6.72 (d,J=1.8 Hz, 1H), 6.21 (s, 1H), 5.47 (s, 1H), 5.04 (s, 1H), 3.87-3.80 (m,3H), 3.71-3.63 (m, 2H), 3.56-3.44 (m, 2H), 3.24-3.17 (m, 8H), 2.77 (d,J=20.0 Hz, 2H), 2.29 (s, 4H), 2.20 (s, 2H), 1.99 (s, 2H), 1.42 (t,J=5.24 Hz, 2H), 0.96 (s, 6H).

The compounds below are prepared by methods substantially identical,similar, or analogous to those disclosed in above Schemes and Examples:

m/z Example Chemical Name (MH⁺) Cpd-1(R)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4- 880((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4- yl)methyl)amino)phenyl)sulfonyl)benzamide,Cpd-2 (S)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4- 880((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4- yl)methyl)amino)phenyl)sulfonyl)benzamide,Cpd-3 4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro- 910[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(dimethyl(1H-pyrrolo[2,3-b]pyridin-5-yl)silyl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide, Cpd-4N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3- 917nitrophenyl)sulfonyl)-4-(2-(2-(2- cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)- yl)benzamide, Cpd-54-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7- 945azaspiro[3.5]nonan-7-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide, Cpd-62-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2- 903cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((3-(morpholinomethyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7- yl)sulfonyl)benzamide,Cpd-7 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2- 916cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((3-((4-methylpiperazin-1-yl)methyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide, Cpd-8N-(((S)-3-((R)-1,4-dioxan-2-yl)-5-nitro-3,4-dihydro- 8902H-benzo[b][1,4]oxazin-7-yl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7- azaspiro[3.5]nonan-7-yl)benzamide,Cpd-9 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2- 888cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((5-nitro-3-(tetrahydro-2H-pyran-4-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide.

Biological Example 1: Bcl-2 Competition Binding (FluorescencePolarization) Assay

The fluorescence-labeled 23 amino acid peptide BH3 was purchased fromCalBiochem (NLWAAQRYGRELRRMSDKFVD). An unbound Fluorescein labeled BH3peptide emits random light with respect to the plane of polarizationplane of excited light, resulting in a lower polarization degree (mP)value. When the peptide is bound to Bcl-2, the complex tumble slower andthe emitted light can have a higher level of polarization, resulting ina higher mP value. This binding assay was performed in 96-well plate andwith each assay contained 15 and 30 nM of labeled peptide and purifiedBcl-2 protein (purchased from R&D Systems, Inc). The assay buffercontained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl₂, 20 mM Na₂MoO₄,0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were dilutedin DMSO and added to the final assay with concentration range from 20 μMto 2 nM. The polarization degree (mP) value was determined by BioTekSynergy II with background subtraction after 3 hours of incubation atroom temperature. IC₅₀ was calculated using Prism software withsigmoidal dose-response curve fitting. ABT-737 was used as referencecompound. Such assays, carried out with a range of doses of testcompounds, allowed the determination of an approximate IC₅₀ value.Although the inhibitory properties of the compounds of the presentinvention vary with structural change as expected, the activitygenerally exhibited by these agents was in the range of IC₅₀=0.1-1000nM.

As shown in the following table lists the BCF2 IC₅₀ values, the Example1 and Example 3 are highly potent BCL2 inhibitor.

Compound BCL2 IC50 (nM) ABT-199 0.39 ABT-263 0.45 Example 1 0.45 Example2 0.8 Example 3 1.3

Biological Example 2: In Vitro Anti-Proliferation Assay inBCL-2-Dependent Acute Lymphoblastic Leukemia (ALL) Cell Line RS4;11

Cell antiproliferation was assayed by PerkinElmer ATPlite™ LuminescenceAssay System. Briefly, the various test cancer cell lines were plated ata density of about 1×10⁴ cells per well in Costar 96-well plates, andwere incubated with different concentrations of compounds for about 72hours in medium supplemented with 5% FBS or 10% normal human serum(NHS).One lyophilized substrate solution vial was then reconstituted by adding5 mL of substrate buffer solution, and was agitated gently until thesolution was homogeneous. About 50 μL of mammalian cell lysis solutionwas added to 100 μL of cell suspension per well of a microplate, and theplate was shaken for about five minutes in an orbital shaker at −700rpm. This procedure was used to lyse the cells and to stabilize the ATP.Next, 50 μL substrate solution was added to the wells and microplate wasshaken for five minutes in an orbital shaker at −700 rpm. Finally, theluminescence was measured by a PerkinElmer TopCount® MicroplateScintillation Counter. Such assays, carried out with a range of doses oftest compounds, allowed the determination of the cellularanti-antiproliferative IC₅₀ of the compounds of the present invention.The following table lists the IC₅₀ values of certain compounds of theinvention.

Biological Example 3: Mice PK Study

The pharmacokinetics of compounds were evaluated in CD-1 mouse viaIntravenous and Oral Administration. The IV dose was administered as aslow bolus in the Jugular vein, and oral doses were administered bygavage. The formulation for IV dosing was 5% DMSO in 20% HPBCD in water,and the PO formulation was 2.5% DMSO, 10% EtOH, 20% Cremphor EL, 67.5%D5W. The PK time point for the IV arm was 5, 15, 30 min, 1, 2, 4, 6, 8,12, 24 hours post dose, and for PO arm was 15, 30 min, 1, 2, 4, 6, 8,12, 24 hours post dose.

Approximately 0.03 mL blood was collected at each time point. Blood ofeach sample was transferred into plastic micro centrifuge tubescontaining EDTA-K2 and collect plasma within 15 min by centrifugation at4000 g for 5 minutes in a 4° C. centrifuge. Plasma samples were storedin polypropylene tubes. The samples were stored in a freezer at −75±15°C. prior to analysis. Concentrations of compounds in the plasma sampleswere analyzed using a LC-MS/MS method. WinNonlin (Phoenix™, version 6.1)or other similar software was used for pharmacokinetic calculations. Thefollowing pharmacokinetic parameters were calculated, whenever possiblefrom the plasma concentration versus time data: IV administration: C₀,CL, V_(d), T_(1/2), AUC_(inf), AUC_(last), MRT, Number of Points forRegression; PO administration: C_(max), T_(max), T_(1/2), AUC_(inf),AUC_(last), F %, Number of Points for Regression. The pharmacokineticdata was described using descriptive statistics such as mean, standarddeviation. Additional pharmacokinetic or statistical analysis wasperformed at the discretion of the contributing scientist, and wasdocumented in the data summary.

Biological Example 4: In Vivo Xenograft Studies

Compound of Example 3 is selected for in vivo studies in theBCL-2-dependent acute lymphoblastic leukemia (ALL) RS4;11 xenograftmodel. The CB.17 SCID mice are obtained at age 6-8 weeks from vendorsand acclimated for a minimum 7-day period. The cancer cells are thenimplanted into the nude mice. Depending on the specific tumor type,tumors are typically detectable about two weeks following implantation.When tumor sizes reach ˜100-200 mm³, the animals with appreciable tumorsize and shape are randomly assigned into groups of 8 mice each,including one vehicle control group and treatment groups. Dosing variesdepending on the purpose and length of each study, which typicallyproceeds for about 3-4 weeks. Tumor sizes and body weight are typicallymeasured three times per week. In addition to the determination of tumorsize changes, the last tumor measurement is used to generate the tumorsize change ratio (T/C value), a standard metric developed by theNational Cancer Institute for xenograft tumor evaluation. In most cases,% T/C values are calculated using the following formula: % T/C=100×ΔT/ΔCif ΔT>0. When tumor regression occurred (ΔT<0), however, the followingformula is used: % T/T0=100×ΔT/T0. Values of <42% are consideredsignificant.

What is claimed is:
 1. A compound of Formula (I), or an N-oxide thereof,or a pharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug of said compound of Formula(I) or N-oxide thereof:

wherein Z is —P(═O)(R_(c))—, —C(R_(a)R_(b))—, —C(═C(R_(a)R_(b)))—,—Si(R_(a)R_(b))—, —C(O)—, —N(R⁰)—, —S(═O)(═NR_(c))—, Q₁ is 6-9 memberedheteroaryl; Q₃ is cycloalkyl, cycloalkenyl, bridged cycloalkyl,heterocycloalkyl, heterocycloalkenyl, aryl or heteroaryl; Q₄ iscycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, orheteroaryl; Q₅ is cycloalkyl, cycloalkenyl, heterocycloalkyl,heterocycloalkenyl, aryl, heteroaryl, or spiro heterocyclic; Q₆ is6-membered aryl, or 5-6 membered heteroaryl; Q₇ is 6-membered aryl or5-6 membered heteroaryl, each of which is optionally fused with abenzene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane, orheterocycloalkene; each of R₀, and R⁰, independently, is H or alkyl;each of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀, independently, isH, D, alkyl, spiroalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,heterocycloalkyl, spiroheterocycloalkyl, heterocycloalkenyl, aryl,heteroaryl, halo, nitro, oxo, cyano, OR_(a), SR_(a), alkyl-R_(a),NH(CH₂)_(p)R_(a), C(O)R_(a), S(O)R_(a), SO₂R_(a), C(O)OR_(a),OC(O)R_(a), NR_(b)R_(c), C(O)N(R_(b))R_(c), N(R_(b))C(O)R_(c),—P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c), —S(O)(═N(R_(b)))R_(c),—N═S(O)R_(b)R_(c), ═NR_(b), SO₂N(R_(b))R_(c), or N(R_(b))SO₂R_(c), inwhich said cycloalkyl, cycloalkenyl, heterocycloalkyl,heterocycloalkenyl, aryl, heteroaryl is optionally substituted with oneor more R₄; R_(a), R_(b), R_(c) and R_(d), independently, is H, D,alkyl, spiroalkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy,═O, —P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c), —S(O)(═N(R_(b)))R_(c),—N═S(O)R_(b)R_(c), ═NR_(b), C(O)NHOH, C(O)OH, C(O)NH₂, alkoxy,alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl,alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino,cycloalkyl, cycloalkenyl, heterocycloalkyl, spiroheterocycloalkyl,heterocycloalkenyl, aryl, or heteroaryl, in which said alkyl,cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl,heteroaryl is optionally substituted with one or more R_(e); R_(e) is H,D, alkyl, spiroalkyl, alkenyl, alkynyl, halo, cyano, amine, nitro,hydroxy, ═O, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino,alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl,heterocycloalkyl, spiroheterocycloalkyl, heterocycloalkenyl, aryl, orheteroaryl; W is O or N(R_(a)); Z₁ is a bond, (CH₂)_(P), N(H), O, S,C(O), S(O₂), OC(O), C(O)O, OSO₂, S(O₂)O, C(O)S, SC(O), C(O)C(O),C(O)N(H), N(H)C(O), S(O₂)N(H), N(H)S(O₂), OC(O)O, OC(O)S, OC(O)N(H),N(H)C(O)O, N(H)C(O)S, N(H)C(O)N(H), (CH₂)_(p)N(H)(CH₂)_(q),(CH₂)_(p)N(H)C(O)(CH₂)_(q), (CH₂)_(p)C(O)N(H)(CH₂)_(q),OC(O)N(H)(CH₂)_(p+1)N(H)(CH₂)_(q), a bivalent alkenyl group, or abivalent alkynyl group; L is bond, alkenyl, alkynyl, cycloalkyl,cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl,in which said alkenyl, alkynyl, cycloalkyl, cycloalkenyl,heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl is optionallysubstituted with one or more R_(d); R₀ and R_(a) group, taken togetherwith the atom to which they are attached, may optionally form acycloalkyl or heterocycloalkyl, in which said cycloalkyl orheterocycloalkyl, is optionally substituted with one or more R_(d); R⁰and R₁₀ group, taken together with the atom to which they are attached,may optionally form a cycloalkyl or heterocycloalkyl, in which saidcycloalkyl or heterocycloalkyl, is optionally substituted with one ormore R_(d); two of R_(d) group, taken together with the atom to whichthey are attached, may optionally form a cycloalkyl or heterocycloalkyl,in which said cycloalkyl or heterocycloalkyl of R₁, is optionallysubstituted with one or more R_(d); two of R₂ group, taken together withthe atom to which they are attached, may optionally form a cycloalkyl orheterocycloalkyl, in which said cycloalkyl or heterocycloalkyl of R₂, isoptionally substituted with one or more R_(d); R₃ and R₄ group, takentogether with the atom to which they are attached, may optionally form acycloalkyl or heterocycloalkyl, in which said cycloalkyl orheterocycloalkyl of R₃ or R₄, is optionally substituted with one or moreR_(d); two of R₅ group, taken together with the atom to which they areattached, may optionally form a cycloalkyl or heterocycloalkyl, in whichsaid cycloalkyl or heterocycloalkyl of R₅, is optionally substitutedwith one or more R_(d); R₇ and R₈ group, taken together with the atom towhich they are attached, may optionally form a cycloalkyl orheterocycloalkyl, in which said cycloalkyl or heterocycloalkyl of R₇ orR₈, is optionally substituted with one or more R_(d); R₈ and —Z₁-L-R₆group, taken together with the atom to which they are attached, mayoptionally form a cycloalkyl, cycloalkenyl, heterocycloalkyl,heterocycloalkenyl, aryl, or heteroaryl, in which said cycloalkyl,cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroarylof R₇, is optionally substituted with one or more R_(d); R_(b) and R_(c)group, taken together with the atom to which they are attached, mayoptionally form a cycloalkyl, or heterocycloalkyl, in which saidcycloalkyl or heterocycloalkyl of R_(b) and R_(c), is optionallysubstituted with one or more R_(e); two of R_(d) group, taken togetherwith the atom to which they are attached, may optionally form acycloalkyl, or heterocycloalkyl, in which said cycloalkyl orheterocycloalkyl of R_(d), is optionally substituted with one or moreR_(e); two of R_(e) group, taken together with the atom to which theyare attached, may optionally form a cycloalkyl or heterocycloalkyl, inwhich said cycloalkyl or heterocycloalkyl of R_(e) is optionallysubstituted with one or more groups selected from H, D, alkyl, alkenyl,alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy,alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl,alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino,cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, orheteroaryl; each of g and j is, independently, 0, 1, 2, or 3; each of n,v and k is, independently, 0, 1, 2, 3, 4, 5, 6, 7, or 8; s is 0 or 1;and each of m, p, and q is, independently, 0, 1, 2, 3, 4, or
 5. 2. Thecompound according to claim 1 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is represented by Formula (II):


3. The compound according to claim 2 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is represented by Formula (III):


4. The compound according to claim 3 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is represented by Formula (IV):


5. The compound according to claim 1 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is represented by Formula (A):

wherein Q₄ is heterocycloalkyl; and Q₅ is phenyl or spiro heterocyclic.6. The compound according to claim 5 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is represented by Formula (B):

wherein f is 0, 1, or 2; and Z₂ is O, S, or S(O₂).
 7. The compoundaccording to claim 6 or an N-oxide thereof, or a pharmaceuticallyacceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopicform, or a prodrug thereof, wherein the compound is represented byFormula (C-1) or Formula (C-2):


8. The compound according to claim 7 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is represented by Formula (D-1) or Formula (D-2):


9. The compound according to claim 1 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoryl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(methyl(1H-pyrrolo[2,3-b]pyridin-5-yl)phosphoryl)benzamide,6-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1(2H)-one,2-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-6-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydroisoquinolin-1(2H)-one,2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)vinyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,(R)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,(S)-2-(1-(1H-pyrrolo[2,3-b]pyridin-5-yl)ethyl)-4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,4-(4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)-2-(dimethyl(1H-pyrrolo[2,3-b]pyridin-5-yl)silyl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide,N-((4-((((S)-1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzamide,4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-2-((R)-3-methyl-2,3-dihydropyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazin-1(6H)-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide.10. A pharmaceutical composition comprising a compound of Formula (I) oran N-oxide thereof as defined in claim 1, or a pharmaceuticallyacceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopicform, or a prodrug of said compound of Formula (I) or an N-oxidethereof, and a pharmaceutically acceptable diluent or carrier.
 11. Amethod of treating a neoplastic disease, an autoimmune disease, or aneorodegenerative disease, comprising administering to a subject in needthereof an effective amount of a compound of Formula (I) or an N-oxidethereof as defined in claim 1, or a pharmaceutically acceptable salt,solvate, polymorph, tautomer, stereoisomer, an isotopic form, or aprodrug of said compound of Formula (I) or an N-oxide thereof.
 12. Acompound of Formula (1), or an N-oxide thereof, or a pharmaceuticallyacceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopicform, or a prodrug of said compound of Formula (1) or N-oxide thereof:

wherein Z is —O—, —C(R_(a)R_(b))—, —P(═O)(R_(c))—, —C(═C(R_(a)R_(b)))—,—Si(R_(a)R_(b))—, —C(O)—, —N(R⁰)—, —S(═O)(═NR_(c))—, Q₄ is cycloalkyl,cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;Q₅ is cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl,aryl, heteroaryl, or spiro heterocyclic; each of R₁, R₂, R₅, and R₉,independently, is H, D, alkyl, spiroalkyl, alkenyl, alkynyl, cycloalkyl,cycloalkenyl, heterocycloalkyl, spiroheterocycloalkyl,heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, cyano, OR_(a),SR_(a), alkyl-R_(a), NH(CH₂)_(p)R_(a), C(O)R_(a), S(O)R_(a), SO₂R_(a),C(O)OR_(a), OC(O)R_(a), NR_(b)R_(c), C(O)N(R_(b))R_(c),N(R_(b))C(O)R_(c), —P(O)R_(b)R_(c), -alkyl-P(O)R_(b)R_(c),—S(O)(═N(R_(b)))R_(c), —N═S(O)R_(b)R_(c), ═NR_(b), SO₂N(R_(b))R_(c), orN(R_(b))SO₂R_(c), in which said cycloalkyl, cycloalkenyl,heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionallysubstituted with one or more R₄; R_(a), R_(b), R_(c) and R_(d),independently, is H, D, alkyl, spiroalkyl, alkenyl, alkynyl, halo,cyano, amine, nitro, hydroxy, ═O, —P(O)R_(b)R_(c),-alkyl-P(O)R_(b)R_(c), —S(O)(═N(R_(b)))R_(c), —N═S(O)R_(b)R_(c),═NR_(b), C(O)NHOH, C(O)OH, C(O)NH₂, alkoxy, alkoxyalkyl, haloalkyl,hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl,alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl,cycloalkenyl, heterocycloalkyl, spiroheterocycloalkyl,heterocycloalkenyl, aryl, or heteroaryl, in which said alkyl,cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl,heteroaryl is optionally substituted with one or more R_(e); R_(e) is H,D, alkyl, spiroalkyl, alkenyl, alkynyl, halo, cyano, amine, nitro,hydroxy, ═O, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino,alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl,heterocycloalkyl, spiroheterocycloalkyl, heterocycloalkenyl, aryl, orheteroaryl; Z₃ is a bond, (CH₂)_(P), N(H), O, S, C(O), S(O₂), OC(O),C(O)O, OSO₂, S(O₂)O, C(O)S, SC(O), C(O)C(O), C(O)N(H), N(H)C(O),S(O₂)N(H), N(H)S(O₂), OC(O)O, OC(O)S, OC(O)N(H), N(H)C(O)O, N(H)C(O)S,N(H)C(O)N(H), (CH₂)_(p)N(H)(CH₂)_(q), (CH₂)_(p)N(H)C(O)(CH₂)_(q),(CH₂)_(p)C(O)N(H)(CH₂)_(q), OC(O)N(H)(CH₂)_(p+1)N(H)(CH₂)_(q), abivalent alkenyl group, or a bivalent alkynyl group; L is bond, alkenyl,alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl,aryl, or heteroaryl, in which said alkenyl, alkynyl, cycloalkyl,cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroarylis optionally substituted with one or more R_(d); two of R₁ group, takentogether with the atom to which they are attached, may optionally form acycloalkyl or heterocycloalkyl, in which said cycloalkyl orheterocycloalkyl of R_(d), is optionally substituted with one or moreR_(d); two of R₂ group, taken together with the atom to which they areattached, may optionally form a cycloalkyl or heterocycloalkyl, in whichsaid cycloalkyl or heterocycloalkyl of R₂, is optionally substitutedwith one or more R_(d); two of R₅ group, taken together with the atom towhich they are attached, may optionally form a cycloalkyl orheterocycloalkyl, in which said cycloalkyl or heterocycloalkyl of R₅, isoptionally substituted with one or more R_(d); R_(b) and R_(c) group,taken together with the atom to which they are attached, may optionallyform a cycloalkyl, or heterocycloalkyl, in which said cycloalkyl orheterocycloalkyl of R_(b) and R_(c), is optionally substituted with oneor more R_(e); two of R_(d) group, taken together with the atom to whichthey are attached, may optionally form a cycloalkyl, orheterocycloalkyl, in which said cycloalkyl or heterocycloalkyl of R_(d),is optionally substituted with one or more R_(e); two of R_(e) group,taken together with the atom to which they are attached, may optionallyform a cycloalkyl or heterocycloalkyl, in which said cycloalkyl orheterocycloalkyl of R_(e) is optionally substituted with one or moregroups selected from H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine,nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl,aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino,alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl,heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl; each of m, n,v, p, and q is, independently, 0, 1, 2, 3, 4, or
 5. 13. The compoundaccording to claim 12 or an N-oxide thereof, or a pharmaceuticallyacceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopicform, or a prodrug thereof, wherein the compound is represented byFormula (2):

wherein Q₄ is 5-6 membered heterocycloalkyl.
 14. The compound accordingto claim 13 or an N-oxide thereof, or a pharmaceutically acceptablesalt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or aprodrug thereof, wherein the compound is represented by Formula (3):


15. The compound according to claim 12 or an N-oxide thereof, or apharmaceutically acceptable salt, solvate, polymorph, tautomer,stereoisomer, an isotopic form, or a prodrug thereof, wherein thecompound is2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((3-(morpholinomethyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((3-((4-methylpiperazin-1-yl)methyl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide,N—(((S)-3-((R)-1,4-dioxan-2-yl)-5-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide,2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)-N-((5-nitro-3-(tetrahydro-2H-pyran-4-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)sulfonyl)benzamide.16. A pharmaceutical composition comprising a compound of Formula (1) oran N-oxide thereof as defined in claim 12, or a pharmaceuticallyacceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopicform, or a prodrug of said compound of Formula (1) or an N-oxidethereof, and a pharmaceutically acceptable diluent or carrier.
 17. Amethod of treating a neoplastic disease, an autoimmune disease, or aneorodegenerative disease, comprising administering to a subject in needthereof an effective amount of a compound of Formula (1) or an N-oxidethereof as defined in claim 12, or a pharmaceutically acceptable salt,solvate, polymorph, tautomer, stereoisomer, an isotopic form, or aprodrug of said compound of Formula (1) or an N-oxide thereof.